Remo Panaccione
#115,182
Most Influential Person Now
Researcher
Remo Panaccione's AcademicInfluence.com Rankings
Remo Panaccionecomputer-science Degrees
Computer Science
#4478
World Rank
#4722
Historical Rank
Machine Learning
#887
World Rank
#899
Historical Rank
Artificial Intelligence
#1100
World Rank
#1119
Historical Rank
Database
#1690
World Rank
#1771
Historical Rank
Download Badge
Computer Science
Remo Panaccione's Degrees
- Masters Artificial Intelligence University of Oxford
Similar Degrees You Can Earn
Why Is Remo Panaccione Influential?
(Suggest an Edit or Addition)Remo Panaccione's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. (2012) (4135)
- Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies (2017) (2779)
- Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. (2007) (2091)
- Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. (2006) (1610)
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target (2015) (1329)
- Ustekinumab induction and maintenance therapy in refractory Crohn's disease. (2012) (945)
- The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. (2002) (939)
- Natalizumab induction and maintenance therapy for Crohn's disease. (2005) (887)
- Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial (2007) (792)
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial (2011) (792)
- Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. (2014) (780)
- Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. (2013) (612)
- Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. (2007) (602)
- The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016) (600)
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial (2017) (549)
- Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease (2012) (484)
- Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab (2007) (479)
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. (2019) (472)
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? (2011) (440)
- Invasive potential of gut mucosa‐derived fusobacterium nucleatum positively correlates with IBD status of the host (2011) (423)
- Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. (2008) (375)
- Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. (2008) (374)
- Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial (2015) (338)
- Association of host genome with intestinal microbial composition in a large healthy cohort (2016) (330)
- Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. (2015) (315)
- Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients (2000) (308)
- Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. (2014) (283)
- Inflammatory bowel disease: a Canadian burden of illness review. (2012) (272)
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease (2016) (257)
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials (2017) (248)
- Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. (2015) (229)
- The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association (2010) (218)
- Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. (2019) (214)
- Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases (2009) (212)
- Quantitative Metabolomic Profiling of Serum, Plasma, and Urine by 1H NMR Spectroscopy Discriminates between Patients with Inflammatory Bowel Disease and Healthy Individuals (2012) (206)
- Review article: defining remission in ulcerative colitis (2011) (190)
- The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. (2013) (190)
- Decreasing Colectomy Rates for Ulcerative Colitis: A Population-Based Time Trend Study (2012) (182)
- Crohn’s disease (2020) (179)
- The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. (2015) (171)
- Long-term Efficacy of Vedolizumab for Ulcerative Colitis (2016) (168)
- Combined Seton Placement, Infliximab Infusion, and Maintenance Immunosuppressives Improve Healing Rate in Fistulizing Anorectal Crohn’s Disease (2003) (165)
- Long-term Efficacy of Vedolizumab for Crohn’s Disease (2016) (164)
- Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting (2020) (164)
- Increased Prevalence of Circulating Novel IL-17 Secreting Foxp3 Expressing CD4+ T Cells and Defective Suppressive Function of Circulating Foxp3+ Regulatory Cells Support Plasticity Between Th17 and Regulatory T Cells in Inflammatory Bowel Disease Patients (2013) (163)
- Postoperative complications and mortality following colectomy for ulcerative colitis. (2011) (162)
- Cumulative Incidence of Second Intestinal Resection in Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Studies (2014) (158)
- Cannabis Use Provides Symptom Relief in Patients with Inflammatory Bowel Disease but Is Associated with Worse Disease Prognosis in Patients with Crohn's Disease (2014) (152)
- Hepatosplenic T cell lymphoma in inflammatory bowel disease (2008) (151)
- Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements (2012) (150)
- Microscopic colitis-defining incidence rates and risk factors: a population-based study. (2008) (141)
- Autoimmune Disorders and Extraintestinal Manifestations in First-degree Familial and Sporadic Inflammatory Bowel Disease: A Case–Control Study (2004) (141)
- Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review (2019) (141)
- Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3 (2014) (137)
- Environment and the inflammatory bowel diseases. (2013) (134)
- Successful management of Crohn's disease of the ileoanal pouch with infliximab. (1999) (131)
- Abatacept for Crohn's disease and ulcerative colitis. (2012) (130)
- Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort (2017) (130)
- Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study (2017) (123)
- Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. (2014) (122)
- Adalimumab safety in global clinical trials of patients with Crohn's disease (2009) (122)
- Bowel Ultrasonography in the Management of Crohn's Disease. A Review with Recommendations of an International Panel of Experts (2016) (121)
- Effect of ambient air pollution on the incidence of appendicitis (2009) (118)
- Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease (2010) (113)
- Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis (2019) (111)
- Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease (2013) (108)
- Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease (2008) (107)
- Adalimumab for the treatment of fistulas in patients with Crohn’s disease (2009) (106)
- 52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants (2013) (105)
- Optimising monitoring in the management of Crohn's disease: a physician's perspective. (2013) (104)
- Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease (2011) (102)
- Evidence of endothelial dysfunction in patients with inflammatory bowel disease. (2009) (99)
- Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease (2010) (99)
- Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE (2013) (98)
- A Randomized Trial Comparing High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy for Detection of Colonic Neoplastic Lesions During IBD Surveillance Colonoscopy (2018) (97)
- Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II) (2017) (96)
- Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases (2016) (96)
- Increased Intestinal Permeability is Associated with Later Development of Crohn's Disease. (2020) (94)
- Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey (2009) (93)
- Modern management of perianal fistulas in Crohn’s disease: future directions (2018) (93)
- Development of an index to define overall disease severity in IBD (2016) (92)
- Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean-a Systematic Review. (2020) (92)
- Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process (2012) (92)
- A Randomized Trial of Methotrexate in Combination With Infliximab for the Treatment of Crohn's Disease (2008) (90)
- Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. (2020) (87)
- Postoperative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies. (2015) (86)
- Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases (2011) (86)
- Development and validation of an administrative case definition for inflammatory bowel diseases. (2012) (84)
- Mo2083 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease (2012) (83)
- The Increasing Weight of Crohn's Disease Subjects in Clinical Trials: A Hypothesis-generatings Time-trend Analysis (2013) (83)
- Polyunsaturated fatty acids in inflammatory bowel diseases: a reappraisal of effects and therapeutic approaches. (2013) (78)
- Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period (2020) (77)
- Anaerostipes hadrus comb. nov., a dominant species within the human colonic microbiota; reclassification of Eubacterium hadrum Moore et al. 1976. (2012) (77)
- Up-Regulation of Annexin-A1 and Lipoxin A4 in Individuals with Ulcerative Colitis May Promote Mucosal Homeostasis (2012) (75)
- Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial (2016) (75)
- Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study (2017) (74)
- Review article: dermatological complications of immunosuppressive and anti‐TNF therapy in inflammatory bowel disease (2013) (71)
- Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report (2012) (71)
- Briakinumab for Treatment of Crohn's Disease: Results of a Randomized Trial (2015) (70)
- Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. (2011) (70)
- A pro-resolution mediator, prostaglandin D2, is specifically up-regulated in individuals in long-term remission from ulcerative colitis (2010) (68)
- Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. (2011) (68)
- Targeted Biopsies Identify Larger Proportions of Patients With Colonic Neoplasia Undergoing High-Definition Colonoscopy, Dye Chromoendoscopy, or Electronic Virtual Chromoendoscopy. (2016) (67)
- The Impact of Ulcerative Colitis on Patients’ Lives Compared to Other Chronic Diseases: A Patient Survey (2010) (67)
- Review: Anti-adhesion molecule therapy for inflammatory bowel disease (2010) (66)
- Clinic-based Point of Care Transabdominal Ultrasound for Monitoring Crohn's Disease: Impact on Clinical Decision Making. (2015) (64)
- Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease (2020) (63)
- Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease (2016) (62)
- Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease. (2015) (61)
- The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease (2017) (61)
- Phenotypic features of Crohn's disease associated with failure of medical treatment. (2014) (59)
- Intrasphincteric botulinum toxin versus pneumatic dilatation for achalasia: a cost minimization analysis. (1999) (58)
- Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings (2015) (57)
- Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. (2018) (57)
- Living with inflammatory bowel disease: A Crohn's and Colitis Canada survey. (2015) (55)
- Open: Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow‐up in the PYRAMID Registry (2018) (55)
- Cross-Sectional Analysis of Overall Dietary Intake and Mediterranean Dietary Pattern in Patients with Crohn’s Disease (2018) (55)
- Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease (2019) (55)
- Long‐term safety of vedolizumab for inflammatory bowel disease (2020) (55)
- Drug-Induced Inflammatory Bowel Disease and IBD-Like Conditions (2013) (54)
- Postoperative complications following colectomy for ulcerative colitis: A validation study (2012) (53)
- The Clinical Implications of Nocebo Effects for Biosimilar Therapy (2019) (53)
- Systematic review: the short‐term and long‐term efficacy of adalimumab following discontinuation of infliximab (2009) (52)
- Ulcerative Colitis Patients With Clostridium difficile are at Increased Risk of Death, Colectomy, and Postoperative Complications: A Population-Based Inception Cohort Study (2016) (52)
- Is antibody testing for inflammatory bowel disease clinically useful? (1999) (51)
- Evolving Definitions of Remission in Crohn’s Disease (2013) (49)
- Optimizing the safety of biologic therapy for IBD (2010) (49)
- Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. (2012) (47)
- Nationwide Temporal Trends in Incidence of Hospitalization and Surgical Intestinal Resection in Pediatric Inflammatory Bowel Diseases in the United States from 1997 to 2009 (2013) (47)
- Advances in medical therapy of inflammatory bowel disease. (2005) (45)
- Prevalence and Anatomic Distribution of Serrated and Adenomatous Lesions in Patients with Inflammatory Bowel Disease (2017) (45)
- Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. (2009) (45)
- Exposing the Weaknesses: A Systematic Review of Azathioprine Efficacy in Ulcerative Colitis (2008) (44)
- A Simple Ultrasound Score for the Accurate Detection of Inflammatory Activity in Crohn's Disease (2017) (44)
- Deep Remission: A New Concept? (2013) (44)
- Adalimumab sustains steroid‐free remission after 3 years of therapy for Crohn’s disease (2011) (43)
- Real‐world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease (2018) (43)
- Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. (2020) (43)
- Hematopoietic cell transplantation for Crohn's disease; is it time? (2006) (43)
- Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. (2005) (42)
- Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis (2017) (42)
- Smoking influences the need for surgery in patients with the inflammatory bowel diseases: a systematic review and meta-analysis incorporating disease duration (2016) (41)
- Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review (2018) (41)
- Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. (2021) (40)
- Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials (2022) (40)
- Liver diseases associated with anti‐tumor necrosis factor‐alpha (TNF‐&agr;) use for inflammatory bowel disease (2011) (39)
- Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey (2017) (39)
- Influences of intestinal bacteria in human inflammatory bowel disease. (2010) (39)
- Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis (2019) (39)
- Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials (2022) (39)
- Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease. (2015) (37)
- Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. (2021) (37)
- Responsiveness of Endoscopic Indices of Disease Activity for Crohn’s Disease (2017) (37)
- Isotretinoin and intestinal inflammation: what gastroenterologists need to know (2009) (37)
- FUT2 genotype and secretory status are not associated with fecal microbial composition and inferred function in healthy subjects (2018) (36)
- Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. (2015) (36)
- Review: Optimal use of biologics in the management of Crohn’s disease (2010) (36)
- Human interleukin-4–treated regulatory macrophages promote epithelial wound healing and reduce colitis in a mouse model (2020) (36)
- Giant cell myocarditis, in a patient with Crohn's disease, treated with etanercept--a tumour necrosis factor-alpha antagonist. (2001) (35)
- Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn’s Disease: A Canadian Multi-Centre Observational Cohort Study (2018) (35)
- Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. (2019) (34)
- Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis (2018) (34)
- Opposing Effects of Smoking in Ulcerative Colitis and Crohn's Disease May Be Explained by Differential Effects on Dendritic Cells (2014) (34)
- Beyond white light: optical enhancement in conjunction with magnification colonoscopy for the assessment of mucosal healing in ulcerative colitis (2017) (34)
- Adalimumab Rapidly Induces Clinical Remission and Response in Patients with Moderate to Severe Crohnʼs Disease Who Had Secondary Failure to Infliximab Therapy: Results of the GAIN Study (2006) (33)
- Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study. (2022) (33)
- Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial (2022) (33)
- Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA (2016) (33)
- Population‐based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis (2007) (32)
- Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set (2017) (32)
- Asthma Is Associated With Subsequent Development of Inflammatory Bowel Disease: A Population‐based Case–Control Study (2017) (30)
- Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease (2018) (30)
- Clinical utility of ustekinumab in Crohn’s disease (2018) (30)
- OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study (2021) (29)
- Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study (2019) (29)
- Clinical predictors of thiopurine-related adverse events in Crohn's disease. (2015) (29)
- Crohn’s-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report (2019) (29)
- Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy (2020) (29)
- An international multicenter real-life prospective study of electronic chromoendoscopy score PICaSSO in Ulcerative Colitis. (2020) (28)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial (2011) (28)
- Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis (2018) (28)
- Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease: An International Multicenter Study. (2018) (28)
- Funding a Smoking Cessation Program for Crohn’s Disease: An Economic Evaluation (2015) (28)
- Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial (2022) (28)
- Advances in novel diagnostic endoscopic imaging techniques in inflammatory bowel disease. (2013) (27)
- Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics. (2001) (27)
- Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD. (2021) (27)
- Inflammatory bowel disease patients who leave hospital against medical advice: Predictors and temporal trends (2009) (26)
- Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. (2020) (26)
- Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review. (2015) (25)
- Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm (2017) (25)
- Review: Anti-tumor necrosis factor therapy and influenza: keeping it in perspective (2010) (25)
- IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease? (2019) (25)
- Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease (2013) (25)
- Refractory Crohn's disease of the vulva treated with infliximab: a case report. (2007) (25)
- Serrated adenoma prevalence in inflammatory bowel disease surveillance colonoscopy, and characteristics revealed by chromoendoscopy and virtual chromoendoscopy. (2014) (25)
- Clostridium difficile infection worsens the prognosis of ulcerative colitis. (2014) (24)
- A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn’s disease (ENACT-2) (2004) (24)
- Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis (2018) (24)
- A diversified dietary pattern is associated with a balanced gut microbial composition of Faecalibacterium and Escherichia/Shigella in patients with Crohn's disease in remission. (2020) (24)
- Novel CD8+ T-Cell Subsets Demonstrating Plasticity in Patients with Inflammatory Bowel Disease (2016) (24)
- Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies (2019) (23)
- Crossover Subsets of CD4+ T Lymphocytes in the Intestinal Lamina Propria of Patients with Crohn’s Disease and Ulcerative Colitis (2017) (23)
- Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study (2020) (23)
- Implementing changes in clinical practice to improve the management of Crohn's disease. (2012) (22)
- Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials (2018) (22)
- 847t Adalimumab for Induction of Clinical Remission in Moderately to Severely Active Ulcerative Colitis (2010) (22)
- Review: Efficacy and safety of adalimumab in Crohn's disease (2008) (22)
- Maintenance of Remission over 1 Year in Patients with Active Crohnʼs Disease Treated with Adalimumab: Results of a Blinded, Placebo-Controlled Study (2005) (22)
- Assessment of Variables Associated with Smoking Cessation in Crohn’s Disease (2012) (22)
- The appendix in ulcerative colitis: a not so innocent bystander. (1999) (22)
- 920 Adalimumab Maintains Long-Term Remission in Moderately to Severely Active Crohn's Disease After Infliximab Failure: 1-Year Follow-Up of Gain Trial (2008) (21)
- Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI (2019) (21)
- Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. (2019) (21)
- Author Correction: Crohn’s disease (2020) (20)
- Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme. (2012) (20)
- Transperineal ultrasonography in perianal Crohn disease: A valuable imaging modality. (2015) (20)
- Systematic review: medical therapy for fibrostenosing Crohn’s disease (2020) (20)
- Mechanisms of inflammatory bowel disease. (2013) (20)
- Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). (2020) (20)
- S1051 Methotrexate for the Prevention of Antibodies to Infliximab in Patients With Crohn's Disease (2010) (19)
- Improving the quality of surveillance colonoscopy in inflammatory bowel disease. (2019) (19)
- A Systematic Review for the Development of a Core Outcome Set for Ulcerative Colitis Clinical Trials (2018) (18)
- The Association of Smoking and Surgery in Inflammatory Bowel Disease is Modified by Age at Diagnosis (2016) (18)
- OP004 Early combined immunosuppression for the management of Crohn's disease: A community-based cluster randomized trial (2014) (18)
- Ulcerative colitis-associated hospitalization costs: a population-based study. (2015) (18)
- Fistula-associated anal carcinoma in Crohn’s disease (2018) (18)
- PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system (2022) (18)
- Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial (2019) (18)
- Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab. (2019) (18)
- An evaluation of adalimumab on the risk of hospitalization in patients with Crohnʼs disease, data from CHARM: O-007. (2008) (17)
- Point of Care Ultrasound Accurately Distinguishes Inflammatory from Noninflammatory Disease in Patients Presenting with Abdominal Pain and Diarrhea (2016) (17)
- Patient preferences for maintenance therapy in Crohn’s disease: A discrete-choice experiment (2020) (17)
- OP01 Higher vs. standard adalimumab maintenance regimens in patients with moderately to severely active ulcerative colitis: Results from the SERENE-UC maintenance study (2020) (16)
- Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada. (2001) (16)
- Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry (2019) (16)
- A practical, evidence-based guide to the use of adalimumab in Crohn’s disease (2011) (16)
- Multimodal Immunosuppressant Therapy in Steroid-Refractory Common Variable Immunodeficiency Sprue: A Case Report Complicating Cytomegalovirus Infection (2006) (16)
- OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM (2019) (16)
- S1031 Crohn's Disease Mucosal Healing in Adalimumab-Treated Patients is Affected by Disease Duration: Results From Extend (2010) (16)
- Type I interferons for induction of remission in ulcerative colitis. (2015) (16)
- SAT0130 Long-term safety of adalimumab in patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and crohn’s disease (2013) (16)
- Corrigendum: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? (2011) (16)
- The natural history of fistulizing Crohn's disease: A population-based study (2000) (16)
- 775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study (2021) (16)
- Relevance of monitoring transmural disease activity in patients with Crohn’s disease: current status and future perspectives (2021) (15)
- The role of vedolizumab in patients with moderate-to-severe Crohn’s disease and ulcerative colitis (2016) (15)
- Mediterranean-like dietary pattern associations with gut microbiome composition and sub-clinical gastrointestinal inflammation. (2022) (15)
- Assessment of endoscopic healing by using advanced technologies reflects histologic healing in ulcerative colitis. (2020) (15)
- Anti-Adhesion Molecule Strategies for Crohn Disease (2012) (15)
- Clinical Predictors of the Risk of Early Colectomy in Ulcerative Colitis: A Population-based Study (2017) (15)
- The NOD2-Smoking Interaction in Crohn's Disease is likely Specific to the 1007 fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study (2017) (15)
- Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases (2016) (14)
- Anti-microbial antibody response is associated with future onset of Crohn's disease independent of biomarkers of altered gut barrier function, subclinical inflammation, and genetic risk. (2021) (14)
- OP23 Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study (2021) (14)
- Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension (2022) (14)
- Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies. (2008) (14)
- 1053 Early Combined Immunosuppression for the Management of Crohn's Disease: A Community-Based Cluster Randomized Trial (2014) (13)
- Ulcerative Colitis: Shifting Sands (2019) (13)
- Higher vs Standard Adalimumab Induction Dosing Regimens and 2 Maintenance Strategies: Randomized SERENE CD Trial Results. (2022) (13)
- Clinical Practice Guideline for the Management of Luminal Crohn's Disease: The Toronto Consensus. (2019) (13)
- Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. (2022) (13)
- Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease. (2014) (13)
- OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study (2019) (12)
- 799 – Efficacy of Upadacitinib As an Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis, with Or Without Previous Treatment Failure of Biologic Therapy: Data from the Dose-Ranging Phase 2B Study U-Achieve (2019) (12)
- Preoperative Ustekinumab Treatment is not Associated with Increased Postoperative Complications in crohn's Disease: A Canadian Multicentre Case–Control Cohort Study (2017) (12)
- Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis (2018) (12)
- The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management (2017) (12)
- Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study (2017) (12)
- The Rising Burden of Inflammatory Bowel Disease in North America from 2015 to 2025: A Predictive Model: 1959 (2015) (12)
- 649 A Randomized Placebo-Controlled Trial of Abatacept for Moderately-to-Severely Active Crohn's Disease (CD) (2010) (11)
- Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. (2010) (11)
- Briakinumab (Anti-interleukin 12/23p40, ABT874) for Treatment of Crohnʼs Disease (CD): 1245 (2010) (11)
- Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls (2017) (11)
- Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians (2020) (11)
- Isolated Visceral Small Artery Fibromuscular Hyperplasia-Induced Ischemic Colitis Mimicking Inflammatory Bowel Disease (2004) (11)
- Pregnant Women with Inflammatory Bowel Disease Are at Increased Risk of Vitamin D Insufficiency: A Cross-Sectional Study (2018) (11)
- The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta (2020) (11)
- Review and clinical perspectives for the use of infliximab in ulcerative colitis. (2008) (11)
- Economic Impact of Deep Remission in Adalimumab-Treated Patients With Crohn's Disease: Results From Extend (2011) (11)
- Associations of NOD2 polymorphisms with Erysipelotrichaceae in stool of in healthy first degree relatives of Crohn’s disease subjects (2020) (11)
- Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. (2018) (11)
- Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: An Economic Evaluation (2014) (10)
- Update on ustekinumab for the treatment of Crohn's disease. (2014) (10)
- A202 TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 5.4 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS (2019) (10)
- 624 Final Results of a Randomized Study Comparing High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy Using iSCAN for Detection of Colonic Neoplastic Lesions During IBD Surveillance Colonoscopy (2016) (10)
- Reduction in surgical stoma rates in Crohn's disease: a population‐based time trend analysis (2019) (10)
- Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1. (2022) (9)
- Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force (2020) (9)
- 41a Prediction of Long-Term Clinical Remission for Adalimumab-Treated Patients With Crohn's Disease by Identification of Appropriate Dichotomizing Points for SES-CD (2010) (9)
- I am Jewish: what is my risk of developing Crohn's disease? (2008) (9)
- Su1012 Canadian Patient and Caregiver Perspectives on Subsequent Entry Biologics/Biosimilars for Inflammatory Bowel Disease (2016) (9)
- The Role of Bowel Ultrasound in Detecting Subclinical Inflammation in Pregnant Women with Crohn’s Disease (2018) (9)
- Dietary patterns, food groups and nutrients in Crohn’s disease: associations with gut and systemic inflammation (2021) (9)
- Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response (2019) (9)
- Differential p38 Mitogen-Activated Protein Kinase Target Phosphorylation in Responders and Nonresponders to Infliximab (2003) (9)
- Sa1131 PYRAMID Registry: An Observational Study of Adalimumab in Crohn's Disease: Results at Year 6 (2015) (9)
- Antibodies to mutated citrullinated vimentin and anti‐cyclic citrullinated peptide antibodies in inflammatory bowel disease and related arthritis (2012) (9)
- Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study (2021) (9)
- P150 Responsiveness of endoscopic indices in the evaluation of ulcerative colitis (2014) (8)
- Smoking Is Associated with an Increased Risk for Surgery in Diverticulitis: A Case Control Study (2016) (8)
- Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis Republished (2017) (8)
- Biologic therapy in Crohn's disease: state of the art (2008) (8)
- Juvenile polyposis of the stomach—a novel cause of hypergastrinemia (2010) (8)
- P601 Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn’s disease: Data from the CELEST study (2018) (7)
- S0648 Clinically Adjusted vs Therapeutic Drug Monitoring Dosing Regimens With Adalimumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the SERENE-CD Maintenance Study (2020) (7)
- Past and Future Burden of In fl ammatory Bowel Diseases Based on Modeling of Population-Based Data (7)
- P209 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study. (2017) (7)
- Exploring the role of monitoring anti-TNFα drug and antibody levels in the management of inflammatory bowel disease (2011) (7)
- Adalimumab for the treatment of Crohn's disease (2008) (7)
- DOP065 Long-term cost-effectiveness of tight control for Crohn’s disease with adalimumab-based treatment: economic evaluation beyond 48 weeks of CALM trial (2018) (7)
- Early Laparoscopic Ileal Resection for Localized Ileocecal Crohn’s Disease: Hard Sell or a Revolutionary New Norm? (2021) (7)
- 327 A Randomized Comparison of High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy Using iSCAN for Detection of Colonic Dysplastic Lesions During IBD Surveillance Colonoscopy (2015) (7)
- Anti-MADCAM therapy for ulcerative colitis (2019) (7)
- Granulocyte–monocyte apheresis for the treatment of ulcerative colitis—is this the end of the road? (2009) (7)
- Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn's disease who are antitumour necrosis factor inadequate responders (2016) (7)
- 764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders (2016) (7)
- OP26 Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies (2021) (7)
- Response after 12 Weeks of Adalimumab Therapy in Patients with Crohnʼs Disease Who Were Nonresponders at Week 4: 966 (2008) (7)
- PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis (2022) (6)
- Efficacy and Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Moderately to Severely Active Ulcerative Colitis: 12-Week Results From the Phase 2 LATTICE-UC Study. (2022) (6)
- Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials (2020) (6)
- Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases (2022) (6)
- 856 Efficacy and Safety of Oral Tofacitinib for Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial (2016) (6)
- Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions. (2014) (6)
- Will cross-sectional imaging replace endoscopy for monitoring response to therapy in Crohn's disease? (2014) (6)
- RETRACTED: Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (Psc) in Individuals with Inflammatory Bowel Disease. (2016) (6)
- Sa1812 – Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm (2019) (6)
- Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues (2021) (6)
- Managing the risks of IBD therapy (2009) (6)
- The approach to dysplasia surveillance in inflammatory bowel disease. (2006) (6)
- Long-Term Efficacy of Vedolizumab Therapy for Patients With Ulcerative Colitis: Presidential Poster: 1616 (2014) (6)
- Medical therapy of Crohn disease (2004) (6)
- Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants. (2021) (6)
- Smoking may reduce the effectiveness of anti-TNF therapies to induce clinical response and remission in Crohn's disease: a systematic review and meta-analysis. (2020) (5)
- DOP13 Artificial Intelligence (AI) in endoscopy - Deep learning for detection and scoring of Ulcerative Colitis (UC) disease activity under multiple scoring systems (2021) (5)
- PYRAMID registry: An observational study of adalimumab in Crohnʼs disease: results at year 3: P-31. (2011) (5)
- Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment. (2022) (5)
- A virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic activity/remission and predict clinical outcomes in ulcerative colitis (2022) (5)
- Vedolizumab for the treatment of ulcerative colitis (2016) (5)
- P068 MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (2020) (5)
- P300 Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease (2012) (5)
- Endoscopic remission assessed with PICaSSO virtual electronic chromendoscopy accurately predicts clinical outcomes in ulcerative colitis. (2022) (5)
- Commentary: detection of infliximab levels and anti‐infliximab antibodies (2013) (5)
- DOP024 Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2 (2018) (5)
- Adalimumab Safety in Crohnʼs Disease Patients: Open-Label Maintenance Following the Gain and CHARM Trials: 1031 (2007) (5)
- Novel concepts in inflammatory bowel disease. (2014) (5)
- 922 Adalimumab Maintains Long-Term Remission in Moderately to Severely Active Crohn's Disease Through 2 Years (2008) (5)
- Novel Microbial-Based Immunotherapy Approach for Crohn's Disease (2019) (5)
- Natalizumab Maintains Remission for 2 Years in Patients with Moderately to Severely Active Crohnʼs Disease and in Those with Prior Infliximab Exposure: Results from an Open-Label Extension Study (2006) (5)
- Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults (2022) (5)
- Long-Term Safety of Adalimumab in Patients with Crohn's Disease: Final Data from Pyramid Registry (2017) (5)
- OP28 The effect of guselkumab induction therapy on early clinical outcome measures in patients with Moderately to Severely Active Crohn’s Disease: Results from the phase 2 GALAXI 1 study (2021) (5)
- Healthcare Providers Underestimate Patients’ Glucocorticoid Use in Crohn’s Disease (2019) (5)
- Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme (2022) (5)
- Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease (2022) (5)
- Corticosteroid Dose Reduction in Ulcerative Colitis Patients Treated With Vedolizumab During the GEMINI 1 Trial: 1859 (2015) (5)
- P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications (2022) (5)
- OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 study (2022) (5)
- Sa1204 Deep Remission As a Predictor of Clinical Outcomes in Vedolizumab-Treated Patients With Ulcerative Colitis (2015) (4)
- T1131 Steroid-Free Remission Over 2 Years in Crohn's Patients Receiving Adalimumab: the Open-Label Extension of the CHARM Trial (2008) (4)
- Sa1758 - Upadacitinib Improves Steroid-Free Clinical and Endoscopic Endpoints in Patients with Crohn's Disease: Data from the Celest Study (2018) (4)
- P712 Tofacitinib efficacy in patients with moderate to severe ulcerative colitis: Subgroup analyses of OCTAVE Induction 1 and 2 and OCTAVE Sustain by 5-aminosalicylates use (2019) (4)
- P002 Adalimumab Maintains Long-Term Remission in Crohn's Disease through 2 Years (2008) (4)
- The Incidence of Cardiovascular Events in Patients with Crohn’s Disease Treated with Vedolizumab and Anti-TNF Therapies (2017) (4)
- OP015 Biomarker correlation with endoscopic outcomes in patients with Crohn’s disease: data from CALM (2018) (4)
- Corticosteroid Dose Reduction With Vedolizumab Treatment of Crohnʼs Disease During the GEMINI 2 Trial: 1857 (2015) (4)
- Sa1754 Distinctive Th17 Lymphocyte Plasticity in Intestinal Lamina Propria of IBD Patients Compared With Healthy Controls (2015) (4)
- A80 IMPACT OF THE COVID-19 PANDEMIC IN IBD PATIENT CARE (2021) (4)
- P353 Long-term safety of adalimumab in patients with Crohn's disease: final data from PYRAMID registry. (2017) (4)
- Pre-operative exposure to ustekinumab: A risk factor for postoperative complications in Crohn's disease (CD)? (2019) (4)
- OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis (2022) (4)
- Accuracy of Administrative Data in Identifying Ulcerative Colitis Patients Presenting with Acute Flare and Undergoing Colectomy: 2010 Presidential Poster: 1270 (2010) (4)
- DOP071 Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn’s disease: data from CALM (2018) (4)
- DOP023 Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trials (2018) (4)
- OP26 The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in ulcerative colitis (2020) (4)
- P067 Natalizumab Induces Sustained Response and Remission in Crohn's Patients With Previous Infliximab Failure: Results From The Encore Trial (2007) (4)
- DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis (2022) (4)
- S777 Tofacitinib for the Treatment of Ulcerative Colitis: Up to 7.8 Years of Safety Data from Global Clinical Trials (2021) (4)
- 904 - Tofacitinib for the Treatment of Ulcerative Colitis: Up to 4.4 Years of Safety Data from Global Clinical Trials (2019) (4)
- P256 Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel iSCAN endoscopic and refined histological gradings (2014) (4)
- Early Serum Infliximab Levels in Pediatric Ulcerative Colitis (2021) (4)
- CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. (2022) (4)
- UEG Week 2016 Poster Presentations (2016) (4)
- Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review with Temporal Analyses. (2022) (4)
- Clinical course and complications of ulcerative colitis and ulcerative proctitis (2003) (4)
- A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY (2022) (4)
- OP15 A new simplified histology artificial intelligence system for accurate assessment of remission in Ulcerative Colitis (2022) (4)
- The Effects of Maintenance Therapy With Upadacitinib on Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 U-ACHIEVE Maintenance Results. (2022) (4)
- S0703 Tofacitinib for the Treatment of Ulcerative Colitis: Up to 6.8 Years of Safety Data From Global Clinical Trials (2020) (4)
- S695 Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn’s Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies (2021) (4)
- Medical management of inflammatory bowel disease among Canadian gastroenterologists. (2011) (4)
- P008 - Adalimumab sustains quality-of-life improvements in patients with Crohn's disease: 3-year data from CHARM (2009) (4)
- Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. (2022) (4)
- Sa1787 – The Progression of Inflammatory Bowel Disease Throughout Latin America: A Systematic Review (2019) (4)
- Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study (2022) (3)
- Editorial: different tests for different drugs in Crohn’s disease, or different tests for different people? (2017) (3)
- Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary (2021) (3)
- Sa1196 Responsiveness of Endoscopic Indices in the Evaluation of Ulcerative Colitis (2014) (3)
- Identification of Subgroups of Adalimumab-Treated Patients With Crohn's Disease Who Experience High Rates of Deep Remission (2011) (3)
- S715 Clinical and Endoscopic Improvements With Risankizumab Induction and Maintenance Dosing versus Placebo Are Observed Irrespective of Number of Prior Failed Biologics (2022) (3)
- P254 Re-defining the concept of endoscopic and histological healing by using electronic virtual chromoendoscopy and probe confocal endomicroscopy in ulcerative colitis (2019) (3)
- Tu1303 Risk of Surgery Following Diagnosis in Adult and Pediatric Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis (2012) (3)
- Natalizumab Does Not Require the Concomitant Use of Immunosuppressants or Corticosteriods for the Induction of Sustained Response and Remission in Patients with Crohnʼs Disease: 1025 (2007) (3)
- Erratum to: A Diversified Dietary Pattern Is Associated With a Balanced Gut Microbial Composition of Faecalibacterium and Escherichia/Shigella in Patients With Crohn's Disease in Remission. (2020) (3)
- Tu1106 Observer Agreement and Construct Validity in Central Endoscopic Assessment of Disease Activity in Ulcerative Colitis (2013) (3)
- DOP021 Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study. (2017) (3)
- Fr532 THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDY (2021) (3)
- P296 Effect of upadacitinib on patient-reported symptoms by the new Ulcerative Colitis Symptoms Questionnaire (UC-SQ) in patients with moderate to severe ulcerative colitis: data from the Phase 2b study U-ACHIEVE (2019) (3)
- Corrigendum: Surgical Rates for Crohn’s Disease Are Decreasing: A Population-Based Time Trend Analysis and Validation Study (2018) (3)
- Adalimumab Efficacy and Safety by Disease Duration: Analysis of Pooled Studies of Crohn's Disease (2017) (3)
- S0845 Pharmacokinetics and Immunogenicity of Maintenance Therapy With Ustekinumab: 2-Year Results From the UNIFI Long-Term Extension Study (2020) (3)
- P319 Inflammatory uncomplicated phenotype at the start of biological therapy predicts best surgery-free outcomes (2012) (3)
- Sa1102 Post-Operative Mortality for the Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Studies (2014) (3)
- Evaluation of an integrated yoga program in patients with inflammatory bowel disease: A pilot study. (2021) (3)
- Tu1272 Cumulative Incidence of First Intestinal Surgery in Adult and Pediatric Crohn's Disease: A Systematic Review and Meta-Analysis (2012) (3)
- S856 Efficacy of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis by Biologic Inadequate Responder Status: Results From Two Randomized Phase 3 Studies (2021) (3)
- OP0233 Long-term safety of adalimumab in adult patients from global clinical trials across multiple indications: an updated analysis in 29,987 patients representing 56,951 patient-years (2018) (3)
- Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open (2022) (3)
- P006 Adalimumab Maintains Long-Term Remission in Crohn's Disease after Infliximab Failure: 1-Year Follow-up of Gain Trial (2008) (3)
- Sa1779 – Hospitalizations for IBD Throughout the World: A Systematic Review with Temporal Analyses (2019) (3)
- P717 The use of combination biologic therapy in inflammatory bowel disease: A single tertiary-centre experience (2019) (3)
- Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations (2021) (3)
- OP40 Efficacy of risankizumab induction and maintenance therapy by baseline Crohn’s Disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies (2022) (3)
- Efficacy of Ustekinumab for Ulcerative Colitis Through 2 Years: Results of the UNIFI Maintenance Study and Long-term Extension (2020) (3)
- Long-Term Adalimumab Treatment Is Associated with Sustained Fistula Healing in Patients with Moderate to Severe Crohnʼs Disease: 1067 (2008) (2)
- S0881 Therapeutic Drug Monitoring Dosing Regimen With Adalimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the SERENE-UC Maintenance Study (2020) (2)
- 867f: EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO FAILED PRIOR BIOLOGICS: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEED STUDY (2022) (2)
- P112 iSCAN-High definition colonoscopy correlates with white light endoscopy and histology assessment in mucosal healing for ulcerative colitis (2013) (2)
- P757 Long-term effectiveness and safety of adalimumab based on Crohn’s disease duration: Results from the PYRAMID registry (2018) (2)
- 325 - Factors Driving Treatment Escalation in Crohn's Disease in the Calm Trial (2018) (2)
- P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials (2022) (2)
- P274 Factors driving treatment escalation in Crohn’s disease in the CALM trial (2018) (2)
- S851 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: PROMIS-29 in the SEAVUE Study (2021) (2)
- Clinical disease activity in the CALM study – Authors' reply (2018) (2)
- Serological Responses to the First Three Doses of SARS-CoV-2 Vaccination in Inflammatory Bowel Disease: A Prospective Cohort Study (2022) (2)
- Long‐Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis: P‐19 (2012) (2)
- P005 DELAY IN DIAGNOSIS OF ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY (2019) (2)
- 812f Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals With Inflammatory Bowel Disease (2016) (2)
- A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohnʼs Disease: Data From CALM 2017 ACG Governors Award for Excellence in Clinical Research: 598 (2017) (2)
- A228 GASTROENTEROLOGISTS DIFFER IN THEIR PREFERRED MODE OF DELIVERY FOR PREGNANT WOMEN WITH ILEAL ANAL-POUCH ANASTOMOSIS (2018) (2)
- Association of Circulating Fibrocytes With Fibrostenotic Small Bowel Crohn's Disease. (2021) (2)
- Decreasing Colectomy Rates for Ulcerative Colitis Patients Following Increased Utilization of Immunomodulators and Biologics: A Population-Based Time Trend Study (2011) (2)
- 836 Tofacitinib Efficacy in Patients With Moderate to Severe Ulcerative Colitis: Subgroup Analyses of OCTAVE Induction 1 & 2 and OCTAVE Sustain by 5-Aminosalicylates Use (2019) (2)
- P380 Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn’s disease (2022) (2)
- PYRAMID Registry: Long-term Safety and Effectiveness of Adalimumab by Baseline Immunomodulator Use in Patients With Crohnʼs Disease: 694 (2017) (2)
- 279 COMBINATION THERAPY DOES NOT IMPROVE CLINICAL AND ENDOSCOPIC REMISSION RATES WITH VEDOLIZUMAB OR USTEKINUMAB IN CROHN'S DISEASE AND ULCERATIVE COLITIS (2020) (2)
- ADALIMUMAB, A HUMAN ANTI-TNF-α MONOCLONAL ANTIBODY, INDUCES CLINICAL REMISSION AND RESPONSE IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHNʼS DISEASE IRRESPECTIVE OF SMOKING STATUS: 800 (2004) (2)
- Differential Effect of Genetic Burden on Disease Phenotypes in Crohn’s Disease and Ulcerative Colitis in a Canadian Cohort (2020) (2)
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Study of Ustekinumab, a Human Monoclonal Antibody to Il-12/23p40, in Patients with Moderately to Severely Active Crohnʼs Disease: Results through Week 36 from the CERTIFI Trial: 2011 ACG Presidential Poster: 1227 (2011) (2)
- P698 The risk of developing subsequent immune mediated inflammatory diseases: a retrospective matched cohort study. (2017) (2)
- Long-Term Complications Responsible for Hospital Readmission Following a Colectomy for Ulcerative Colitis: A Population-Based Analysis (2011) (2)
- Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. (2021) (2)
- Multimodal Brain MRI of Deep Gray Matter Changes Associated With Inflammatory Bowel Disease. (2022) (2)
- 835 – Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results from the Gemini Lts Study (2019) (2)
- 513 Pregnancy Alters the Pharmacokinetics of Infliximab and Adalimumab in IBD Women (2016) (2)
- The old versus the new: which do you keep in postoperative Crohn's disease? (2018) (2)
- An Unusual Cause of Esophageal Obstruction and Hematemesis. (2019) (2)
- Frequency of Opioid Prescription at Emergency Department Discharge in Patients with Inflammatory Bowel Disease: A Nationwide Analysis (2020) (2)
- Su1796 - Biomarker Correlation with Endoscopic Outcomes in Patients with Crohn's Disease: Data from Calm (2018) (2)
- Review article: therapeutic targets for the pharmacologic management of coeliac disease—the future beyond a gluten‐free diet (2022) (2)
- P257 Importance of deep remission compared with mucosal healing only: Results from EXTEND (2012) (2)
- DOP41 Temporal Trends in the epidemiology of Inflammatory Bowel Diseases in the public healthcare system in Brazil: A large population-based study (2021) (2)
- SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY (2022) (2)
- Sa1997 Monitoring Crohns Disease Activity in Children: A Retrospective Comparison of Transabdominal Ultrasound and Ileocolonoscopy (2012) (2)
- A114 SYSTEMATIC REVIEW AND META-ANALYSIS: ENDOSCOPIC AND HISTOLOGIC PLACEBO RATES IN INDUCTION AND MAINTENANCE TRIALS OF ULCERATIVE COLITIS (2018) (2)
- Challenges and Opportunities in IBD Clinical Trial Design. (2021) (2)
- Adalimumab Therapy maintains steroid-free remission and Fistula Closure in patients with moderate to severe Crohnʼs Disease: Results of an Open-Label Study in Canada (ACCESS): P-0122. (2009) (2)
- Use of combination therapy in IBD (2008) (2)
- OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies (2021) (2)
- Author Correction: Crohn’s disease (2020) (2)
- P124 Sustainability of Adalimumab in Improving the Quality of Life of Patients with Fistulizing Crohn's Disease: 2-Year Data from Charm (2008) (2)
- The Effect of Prolonged Therapy with MMX™ Mesalamine in Patients with Acute, Mild-to-Moderate Ulcerative Colitis: 940 (2007) (2)
- P634 Clinical and endoscopic remission with vedolizumab treatment in ulcerative colitis (2018) (2)
- P043 Long-Term Steroid-Free Remission in Crohn's Patients Receiving Adalimumab: The Charm Trial (2008) (2)
- Venous Thromboembolism in the Hospitalized Ulcerative Colitis Patient (2011) (2)
- Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. (2004) (2)
- Sa1792 – The Incidence of Inflammatory Bowel Disease: Analyzing Historical Trends to Predict the Future (2019) (2)
- OP05 Development of three practical indices for mucosal healing among patients with moderate to severe Crohn's disease (2012) (2)
- Interferon-b-1a in Active Moderate to Severe Ulcerative Colitis: Efficacy and Safety from a Phase IIa Multicenter Study: 1216 (2010) (2)
- 625 Real Time Histology at Endoscopy - Virtual Electronic Chromoendoscopy and Probe Confocal Laser Endomicroscopy Can Assess Fine Details of Inflammatory Changes in Ulcerative Colitis Patients (2016) (2)
- S0683 Absence of Bowel Urgency Is Associated With Improvements in Clinical Outcomes in Patients With Ulcerative Colitis Receiving Mirikizumab (2020) (2)
- Mo1238 Resected Fibrostenotic Intestine From Crohn's Disease Patients Express Significant TNF in Proliferative Fibroblasts and in Extracellular Matrix (2014) (2)
- P367 Vedolizumab and early postoperative complications in non-intestinal surgery: A case-matched analysis (2018) (2)
- Once- or Twice-Daily MMX™ Mesalamine for the Maintenance of Remission of Mild or Moderate Ulcerative Colitis: 939 (2007) (2)
- OP39 Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn’s Disease treated with risankizumab: Results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies (2022) (2)
- P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension (2020) (2)
- Optimizing Outcomes in Hepatitis C: Is Treatment Beyond 48 Weeks Ever Justified? (2006) (2)
- Drug development for ulcerative proctitis: current concepts (2021) (2)
- P083 - Steroid-free remission in patients with Crohn's disease who received adalimumab therapy for at least 3 years: long-term results from CHARM (2009) (2)
- Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel (2016) (2)
- P068 Natalizumab Maintains Remission For 2 Years in Patients With Moderately to Severely Active Crohn's Disease and in Those With Prior Infliximab Exposure: Results From an Open-Label Extension Study (2007) (2)
- Adalimumab Safety in Crohnʼs Disease and Rheumatoid Arthritis Clinical Trials, Reduced Mortality in Rheumatoid Arthritis: 1160 (2006) (2)
- W1097 Steroid-Free Remission and Fistula Closure in Adalimumab-Treated Patients with Moderate to Severe Crohn's Disease: the Access Trial (2009) (2)
- Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and Medications (2021) (2)
- Proteinase 3 (PR3) Autoantibodies as a Serological Marker in Inflammatory Bowel Disease (IBD): 1732 (2013) (2)
- P078 ADALIMUMAB SUSTAINS QUALITY-OF-LIFE IMPROVEMENTS IN PATIENTS WITH CROHN'S DISEASE: 2-YEAR DATA FROM CHARM (2008) (2)
- Tu1717 – Tofacitinib for the Treatment of Ulcerative Colitis: Up to 5.4 Years of Safety Data from Global Clinical Trials (2019) (2)
- The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. (2016) (2)
- Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. (2020) (2)
- Recent advances in the endoscopic assessment of ulcerative colitis (2016) (2)
- Tu1885 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN BIOLOGIC NAÏVE, BIOLOGIC NON-FAILURE, AND BIOLOGIC FAILURE POPULATIONS THROUGH 2 YEARS: UNIFI LONG-TERM EXTENSION (2020) (2)
- Adalimumab Maintains Clinical Remission and Response in Patients with Active Crohnʼs Disease: Results of the CHARM Trial (2006) (1)
- Living with ulcerative colitis: differing perceptions of patients and gastroenterologists: P-040. (2008) (1)
- Point-of-care ultrasound accurately distinguishes inflammatory from noninflammatory disease in patients presenting with abdominal pain and diarrhea. (2017) (1)
- Tu1306 Surgical Rates Have Decreased for Emergent Crohn's Disease Resections While Increasing for Elective Resections: A Population-Based Time Trend Study (2012) (1)
- S773 Rapidity of Symptom Control with Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two Randomized Phase 3 Studies (2021) (1)
- 277: A NEW SIMPLIFIED HISTOLOGY ARTIFICIAL INTELLIGENCE SYSTEM FOR ACCURATE ASSESSMENT OF REMISSION IN ULCERATIVE COLITIS (2022) (1)
- OP16 The first virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic remission in Ulcerative Colitis (2022) (1)
- Tu1848 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 2 YEARS: RESULTS OF THE UNIFI MAINTENANCE STUDY AND LONGTERM EXTENSION (2020) (1)
- Impact of long-term Adalimumab treatment on fistula healing in patients with moderate to severe Crohnʼs Disease: P-0072. (2008) (1)
- INCIDENCE AND PREVALENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES (2022) (1)
- P644 Hospitalization and abdominal surgery rates in CD according to drug-dispensing: a temporal trend analysis from the Brazilian public healthcare national system (2021) (1)
- Ulcerative colitis: patientsʼ perceptions compared with other chronic diseases: P-039. (2008) (1)
- Poster PresentationsP011 GLOBAL SAFETY OF ADALIMUMAB IN CROHN'S DISEASE CLINICAL TRIALS (2008) (1)
- Mo1297 Mode of Delivery in Inflammatory Bowel Disease Patients: A Population-Based Study (2013) (1)
- A115 CLINICAL, RADIOGRAPHIC, AND ENDOSCOPIC REMISSION WITH VEDOLIZUMAB TREATMENT IN CROHN’S DISEASE. (2018) (1)
- P526 Early sonographic response predicts long-term outcome in Crohn’s disease: A prospective cohort study (2018) (1)
- P403 Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE (2012) (1)
- S771 Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study (2021) (1)
- Mo1832 Validation of Administrative Data for Capturing Crohn's Disease Patients Requiring Surgical Bowel Resection (2016) (1)
- EFFICACY ASSESSMENT OF NATALIZUMAB IN PATIENTS WITH CROHNʼS DISEASE AND PRIOR HISTORY OF INFLIXIMAB THERAPY: 831 (2004) (1)
- P205 - Outcome of patients with Crohn's disease and primary sclerosing cholangitis in CHARM and GAIN (2009) (1)
- Results from an Observational Study of Adalimumab in Crohnʼs Disease: The PYRAMID Registry: 1239 (2009) (1)
- A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY (2022) (1)
- P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study (2022) (1)
- Su1262 Downregulation of IL-17 Related Cytokines in the Second Trimester of Pregnancy in Women With IBD Supports Pregnancy Driven Immunomodulatory Effects Involving the Th17 Pathway (2015) (1)
- 07 A SIGNIFICANT DECLINE IN COLECTOMY RATES FOR COLORECTAL CANCER IN PATIENTS WITH ULCERATIVE COLITIS (2019) (1)
- Natalizumab Improves the Health Related Quality of Life (HRQOL) in Crohnʼs Disease Patients: 842 (2005) (1)
- Adalimumab Sustains Deep Remission for 3 Years: Data From CHARM and ADHERE: P‐58 (2012) (1)
- 945 HIGHER VERSUS STANDARD ADALIMUMAB MAINTENANCE REGIMENS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE SERENE-UC MAINTENANCE STUDY (2020) (1)
- Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis (2022) (1)
- S772 Risankizumab Therapy Induces Improvements in Endoscopic Endpoints in Patients With Moderate-To-Severe Crohn’s Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies (2021) (1)
- Mo1208 Timing of Influenza Vaccination Relative to Maintenance Infliximab Infusion in Inflammatory Bowel Disease Patients Does Not Impact Immune Response or Safety of Vaccine (2014) (1)
- P.11.8: Inter-Observer Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients with Crohn’s Disease (2017) (1)
- P163 Quality of life for patients with deep remission vs. clinical remission and deep remission vs. absence of mucosal ulceration: 3-year data from CHARM/ADHERE (2013) (1)
- Are physicians biased in their choices of therapy to recommend to patients with IBD? (2008) (1)
- Sa506 GLOBAL HOSPITALIZATION TRENDS FOR CROHN'S DISEASE AND ULCERATIVE COLITIS: SYSTEMATIC REVIEW WITH TEMPORAL ANALYSES (2021) (1)
- Efficacy and Safety of Oral Janus Kinase Inhibitors for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis (2019) (1)
- IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: the PROCTRIAL Consensus. (2022) (1)
- Paradoxical Trends in Hospitalization Rates for the Inflammatory Bowel Diseases Between the Western World and Newly Industrialized Countries: A Study of the Organization for Economic Cooperation and Development (OECD): 596 (2017) (1)
- PYRAMID Registry: An Observational Study of Adalimumab in Crohnʼs Disease: Results at Year 3: 1168 (2011) (1)
- S1059 The Impact of Natalizumab On the Quality of Life of Patients Exposed to or Failing Anti-TNFα Therapy in the ENACT-2 Trial (2009) (1)
- Immunogenicity of Natalizumab in Crohnʼs Disease Following Continuous or Interrupted Dosing: 1143 (2006) (1)
- Mo1221 Adalimumab Maintains Remission for Up to 4 Years in Patients With Ulcerative Colitis (2014) (1)
- S736 Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results From a Randomized Phase 3 U-EXCEL Study (2022) (1)
- Natalizumab induces and maintains continuous response and remission in patients with active Crohnʼs disease despite prior anti-tumor necrosis factor-alpha treatment: O-033. (2008) (1)
- A107 POSTOPERATIVE OUTCOMES AMONG USTEKINUMAB TREATED CROHN’S DISEASE PATIENTS: A MULTICENTRE CANADIAN PROVINCIAL EXPERIENCE (2018) (1)
- AGA AbstractsTu1914 PYRAMID Registry: An Observational Study of Adalimumab in Crohn's Disease: Results at Year 7 (2016) (1)
- Nutrition Center of Excellence (COE) in Inflammatory Bowel Disease—A Model and Rationale for Development (2018) (1)
- P508 Dose adjustment in patients with moderate to severe ulcerative colitis: results from year 3 of the UNIFI maintenance study long-term extension (1)
- P006 - Sustainability of adalimumab in improving the quality of life of patients with fistulizing Crohn's disease: 3-year data from CHARM (2009) (1)
- 451 - Immune Checkpoint-Associated Colitis: Incidence, Clinical Course, Diagnostic Findings, and Treatment Response from a Large North American Multi-Center Cohort (2018) (1)
- Su1261 Serum TNF- α Level Changes During Pregnancy Are Associated With Timing of Delivery in IBD Patients (2015) (1)
- Sa1692 - Vedolizumab and Early Postoperative Complications in Nonintestinal Surgery: A Case-Matched Analysis (2018) (1)
- PTH-072 Corticosteroid Dose Reduction in Ulcerative Colitis Patients Treated with Vedolizumab (2016) (1)
- P518 Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE) (2023) (1)
- A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by Qbeco in Subjects with Moderate to Severe Crohn’s Disease (2017) (1)
- A29 THE EVOLVING INCIDENCE OF INFLAMMATORY BOWEL DISEASE: WHAT WILL THE FUTURE HOLD? (2019) (1)
- Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy (2021) (1)
- DOP84 Risankizumab maintenance therapy results in sustained improvements in endoscopic outcomes in patients with moderate to severe Crohn’s Disease: Post-hoc analysis from the phase 3 study FORTIFY (2022) (1)
- Age at Diagnosis of Crohnʼs Disease May Explain NOD2-Smoking Interactions: 1975 (2015) (1)
- P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn’s disease (2023) (1)
- PTU-055 Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis (2013) (1)
- P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study (2021) (1)
- S693 Impact of Prior Biologic Exposure on Patient Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study (2021) (1)
- DOP039 Exploring stoma rates in Crohn’s disease in the biologic era: a population-based time trend analysis (2018) (1)
- Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn’s Disease (2017) (1)
- Improvement in Patient Quality of Life during Treatment with Infliximab, Azathioprine, or Combination Infliximab+Azathioprine for Moderate-to-severe Ulcerative Colitis: 1806 (2013) (1)
- P055 - The ACCESS trial: impact of adalimumab on remission, response and quality of life in patients with Crohn's disease (2009) (1)
- Air Pollution and Appendicitis: a Novel Association (2008) (1)
- Long-term Effectiveness of Adalimumab in Crohnʼs Disease: Observational Data from the PYRAMID Registry: 1804 (2013) (1)
- Su1925 Development of Three Practical Indices for Mucosal Healing Among Patients With Moderate to Severe Crohn's Disease (2012) (1)
- Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease (2022) (1)
- Rapid Response to Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severely Active Crohnʼs Disease in the CLASSIC Study: 850 (2005) (1)
- S770 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: IBDQ in the SEAVUE Study (2021) (1)
- Natalizumab is effective without the concomitant use of immunosuppressants or corticosteroids for the induction and maintenance of response and remission in patients with Crohnʼs disease: P-069. (2008) (1)
- Adalimumab Long-term Effectiveness in Adalimumab-Naive Patients With Crohnʼs Disease: Final Data From PYRAMID Registry: 657 (2017) (1)
- P006 DISCORDANCE OF COMMUNICATION PRIORITIES BETWEEN HEALTHCARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY (2019) (1)
- Tu1954 Colonic Confocal Laser Endomicroscopy Findings in Patients With Primary Sclerosing Cholangitis (2013) (1)
- Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? (2020) (1)
- P509 Evaluating clinical practice patterns with inflammatory bowel disease health care assessment questionnaires (POLARIS): a patient- and a physician-reported survey (2013) (1)
- S743 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results From the UNIFI Long-Term Extension (2022) (1)
- Tu1219 Clinical Outcome of Ulcerative Colitis Patients With Complete Mucosal Healing but With Subtle Abnormalities Detected by Novel iSCAN Endoscopic (2015) (1)
- P435 Rapidity of symptomatic and inflammatory biomarker improvements following upadacitinib induction treatment: data from the U-ACHIEVE study (2019) (1)
- The Comparative Efficacy of Remission Maintenance Therapy in Crohnʼs Disease: A Bayesian Network Meta-analysis: 1774 (2013) (1)
- A28 RELATIVE RATES OF ULCERATIVE COLITIS TO CROHN’S DISEASE: PARALLEL EPIDEMIOLOGIES IN NEWLY VS. HIGHLY INDUSTRIALIZED COUNTRIES (2020) (1)
- Tu1450: EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY (2022) (1)
- T1138 Global Safety of Adalimumab in Crohn's Disease Clinical Trials (2008) (1)
- DOP83 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension (2021) (1)
- 46 THE FIRST REAL-LIFE MULTICENTRE, INTERNATIONAL, PROSPECTIVE VALIDATION STUDY OF THE ELECTRONIC CHROMOENDOSCOPY SCORING SYSTEM (PICASSO-THE PADDINGTON INTERNATIONAL VIRTUAL CHROMOENDOSCOPY SCORE) AND ITS OUTCOME IN ULCERATIVE COLITIS PATIENTS (2020) (1)
- P148 - Adalimumab maintains long-term remission in patients with moderately to severely active Crohn's disease through 3 years of therapy (2009) (1)
- S0779 Effect of Ustekinumab Maintenance Therapy on Stool Frequency and Rectal Bleeding Through 2 Years in the UNIFI Phase 3 Study in Ulcerative Colitis (2020) (1)
- DOP82 Achievement of steroid-free remission in patients with moderately to severely active Crohn’s Disease during treatment with risankizumab (2022) (1)
- Chronic Diarrhea and Malabsorption (2011) (1)
- Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis (2022) (1)
- Natalizumab Induces Sustained Response and Remission in the Absence of Concomitant Immunosuppressants in Patients with Crohnʼs Disease Who Failed Prior Anti-TNFα Therapy: 1022 (2007) (1)
- Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis (2023) (1)
- Constrained multiple instance learning for ulcerative colitis prediction using histological images (2022) (1)
- S0682 Absence of Bowel Urgency Is Associated With Significantly Improved Inflammatory Bowel Disease Related Quality of Life in a Phase 2 Trial of Mirikizumab in Patients With Ulcerative Colitis (2020) (1)
- Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohn's diseaseP-39. (2011) (1)
- Updates from the front lines of Crohn's disease: Achieving a balance between safety and efficacy (2008) (1)
- OP38 Tofacitinib for the treatment of Ulcerative Colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trials (2022) (1)
- P354 Objectively measured time spent sitting, standing upright, and stepping is associated with disease severity and faecal calprotectin in patients with ulcerative colitis (2020) (1)
- S754 Risankizumab as Induction Therapy in Patients with Moderately to Severely Active Crohn’s Disease Who Failed 1 vs >1 Prior Biologic Treatment: Results From the MOTIVATE Study (2021) (1)
- Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database (2018) (1)
- 626 Beyond White Light: The First Experience With the New Green-Red-Orange Light Optical Enhancement Magnification Colonoscopy to Define Fine Details of Mucosal Inflammation in Ulcerative Colitis Patients (2016) (1)
- Harnessing localised delivery of gut-selective therapy for ulcerative colitis. (2020) (1)
- Indications for Elective Caesarean Section in IBD: A Population-based Study: 1736 (2013) (1)
- Impact of Adalimumab therapy after 12 Weeks In patients with Crohnʼs Disease who were non res ponders at week4: P-0059. (2008) (1)
- Safety of Adalimumab in Global Clinical Trials of Patients with Crohnʼs Disease: 1142 (2010) (1)
- Mo1205 Endoscopic Assessment of Mucosal Healing in Crohn's Disease by Novel iSCAN Endoscopic and Refined Histological Gradings (2015) (1)
- PTH-077 De-escalating therapy in patients with crohn’s disease receiving adalimumab: subgroup analysis of the calm study (2019) (1)
- 259 Specific Crohn's Disease (CD) Associated Risk Alleles Are Associated With the Composition of the Intestinal Microbiota in Healthy First Degree Relatives (FDR) of CD Subjects (2013) (1)
- The Access Trial: Adalimumab Improves Work Productivity in Patients with Crohnʼs Disease (2008) (1)
- 700 Protease-Activated Receptor-4 (PAR4) Activation: Evidences for Its Role and Activation in the Pathogenesis of Colitis and in Inflammatory Bowel Diseases (2009) (1)
- T1012 Long-Term Maintenance of Clinical Remission With Reduced Dosing Frequency of Adalimumab in Patients With Moderate to Severe Crohn's Disease (2010) (1)
- OP0076 Risk of developing additional immune mediated manifestations for patients with systemic arthritides (2017) (1)
- The Incidence of Inflammatory Bowel Disease Across Time and Geography: A Systematic Review: 1264 (2010) (1)
- Sa1757 – Improvement in Disease Activity is Associated with Less Disability in a Prospective Study of Pediatric Transition Patients with Ibd (2019) (1)
- Tu1727 – Rapidity of Symptomatic and Inflammatory Biomarker Improvements Following Upadacitinib Induction Treatment: Data from the U-Achieve Study (2019) (1)
- DOP14 Validation of a new OPtical diagnosis Training platform to Improve dysplasia Characterisation in Inflammatory Bowel Disease (OPTIC-IBD): A multicentre randomised controlled study (2022) (1)
- S692 Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 U-ACHIEVE Study (2021) (1)
- Ustekinumab is Effective for Inducing Clinical, Endoscopic, and Radiographic Response and Remission in Refractory Moderate-to-Severe Crohn's Disease: A Multicentre Cohort Study (2017) (1)
- Tu1886 DOSE ADJUSTMENT IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE UNIFI MAINTENANCE STUDY LONG-TERM EXTENSION (2020) (1)
- Remission and Clinical Response Induced and Maintained in Patients with Active Crohnʼs Disease Treated for 1-Year Open-Label with Adalimumab: 858 (2005) (1)
- Congress of the European Crohn ’ s and Colitis Organisation ( ECCO ) in Vienna , Austria Chairperson : (2018) (1)
- Retraction notice to: PS124-Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease [J Hepatol 64 (2016) S199]. (2017) (1)
- Effect of Rural Living on the Development of the Inflammatory Bowel Diseases: A Nested Case-control Study: 1252 (2011) (1)
- Benefit-risk assessment of the TNF-antagonists adalimumab and certolizumab pegol for maintenance treatment of Crohnʼs disease: P-35. (2011) (0)
- A VIRTUAL CHROMOENDOSCOPY ARTIFICIAL INTELLIGENCE SYSTEM TO DETECT ENDOSCOPIC AND HISTOLOGIC REMISSION IN ULCERATIVE COLITIS (2022) (0)
- Sa1164 Treatment of Crohn's Disease With Anti-Tumor Necrosis Factor Decreases Levels of C-Reactive Protein: A Systematic Review and Meta-Analysis (2013) (0)
- Adalimumab maintains long-term remission through 2 years in patients with moderate to severe Crohnʼs Disease: P-0085. (2008) (0)
- Mo1767 – Pediatric Onset Inflammatory Bowel Disease is Not Associated with More Disability Compared to Adult Onset Disease (2019) (0)
- Medical induction of active Crohn's ileitis: evidence-based management. (2008) (0)
- A131 ELECTRONIC HEALTH RECORD–BASED SMARTSETS INTEGRATE VARIOUS ASPECTS OF FLARE MANAGEMENT IN OUTPATIENTS WITH INFLAMMATORY BOWEL DISEASE THEREFORE ENSURING CONTINUITY OF CARE (2018) (0)
- P578 Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials (2023) (0)
- T1049 A Survey Evaluating Patterns of Infliximab Use Amongst Canadian Gastroenterologists: Utilization of the Tailored Design Method (2008) (0)
- T1156 Risk-Aversion Profile of Crohn's Patients: A Feasibility Study for Stem Cell Transplantation (2008) (0)
- Su1215 Evaluating Clinical PRactice Patterns With InflammatORy Bowel Disease HeaLTh CArE Assessment QuestIOnnaireS (POLARIS): A Patient- and a Physician-Reported Survey (2013) (0)
- THE GUT : THE IMPORTANCE OF CONTROLLING SYSTEMIC INFLAMMATION IN INFLAMMATORY BOWEL DISEASE (2016) (0)
- P700 The GEM Project: Stool metabolomic profile is associated with microbiome risk score and with future onset of Crohn’s disease in healthy first-degree relatives (2022) (0)
- P692 Exploring relationships between microbiome, faecal calprotectin and healthy eating index in patients with ulcerative colitis: Interim analyses of a randomised controlled trial (2020) (0)
- A155 REAL-WORLD USE OF CORTIMENT IN ULCERATIVE COLITIS: A POPULATION-BASED STUDY (2021) (0)
- UvA-DARE ( Digital Academic Repository ) Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis : results of a randomised controlled trial (2017) (0)
- Screening for Dysplasia in Primary Sclerosing Cholangitis – A Population-Based Assessment of Physician Practices: 851 (2005) (0)
- A4 DIAGNOSIS OF ASTHMA IS ASSOCIATED WITH SUBSEQUENT DEVELOPMENT OF INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED CASE-CONTROL STUDY (2018) (0)
- Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review (2023) (0)
- Mo1479: PERIANAL FISTULA CLOSURE IN PATIENTS RECEIVING USTEKINUMAB: RESULTS FROM THE SEAVUE AND STARDUST TRIALS (2022) (0)
- Safety of adalimumab in global clinical trials of patients with Crohn's disease. (2011) (0)
- A107 VISCERAL ADIPOSE TISSUE VOLUME DIFFERENTIATES BETWEEN FIBROSTENOTIC AND INFLAMMATORY CROHN’S DISEASE (2023) (0)
- Adalimumab Long-Term Effectiveness in Adalimumab-Naïve Patients with Crohn's Disease: Final Data from Pyramid Registry (2017) (0)
- Sa1229 Durable Clinical Remission and Response in Adalimumab-Treated Patients With Ulcerative Colitis (2015) (0)
- Characterization of Creatine Kinase Levels in the Tofacitinib Ulcerative Colitis Development Program (2018) (0)
- Mo1585: GUT MICROBIOME AND DISEASE ACTIVITY IN ULCERATIVE COLITIS: RELATIONSHIP TO DIETARY COMPONENTS AND METABOLIC PATHWAYS (2022) (0)
- Su1218 Cigarette Smoke Extract Differentially Affects Expression of CD11c in Monocyte-Derived Dendritic Cells in Crohn's Disease Patients With Active Versus Inactive Disease (2015) (0)
- Effect of Adalimumab on Extraintestinal Manifestations Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada (2017) (0)
- Su2000 – Crohn’s Disease Patients in Remission Consuming a Nondiversified Compared with a Diversified Diet Have Altered Gut Microbiota and Decreased Richness (2019) (0)
- Late Breaking Abstracts Submitted to DDW These Abstracts Were Submitted to the AGA in mid-March, Selected by the AGA Council, and Presented During DDW 2004 in New Orleans, Louisiana. (2004) (0)
- Optimal C-Reactive Protein Cutoff Point for Predicting Hospitalization in Patients With Moderately Active Crohn's Disease (2011) (0)
- Symptomatic Improvement Within 3 Days With Tofacitinib Induction Therapy in Patients With Ulcerative Colitis: Results From OCTAVE Induction 1 and 2: 609 (2017) (0)
- S805 Efficacy of Upadacitinib Dose Escalation in a Phase 3 Long-Term Extension Ulcerative Colitis Study (2022) (0)
- A215 PATIENTS WITH INFLAMMATORY BOWEL DISEASE ARE FREQUENTLY PRESCRIBED OPIOID ANALGESICS WHEN DISCHARGED FROM THE EMERGENCY DEPARTMENT (2020) (0)
- Mo1258 Peripartum Complications and Assisted Conception in Crohn's Disease Patients Post Bowel Surgery: A Population-Based Study (2013) (0)
- IBD Patients Who Leave Against Medical Advice: Predictors of the Patient Profile (2008) (0)
- P024 PATIENT AND HEALTHCARE PROVIDER VIEWS ON ULCERATIVE COLITIS TREATMENT GOALS AND QUALITY OF LIFE: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY (2019) (0)
- 398 THE GEM PROJECT: IDENTIFICATION OF A SERUM PROTEOMIC SIGNATURE ASSOCIATED WITH RISK OF FUTURE CROHN'S DISEASE ONSET IN A COHORT OF HEALTHY AT-RISK INDIVIDUALS (2020) (0)
- Tu1250 Use of Azathioprine in a Cohort of Crohn's Disease Patients on Anti-TNF Drugs and Related Surgical Outcomes (2012) (0)
- P580 Improvement in disease activity is associated with less disability in a prospective study of paediatric transition patients with IBD (2019) (0)
- S722 Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Active Ulcerative Colitis Receiving 16 Weeks Extended Induction Treatment Followed by 52 Weeks Maintenance Treatment in U-ACHIEVE/U-ACCOMPLISH Trials (2022) (0)
- Tu1744 The Relationship Between Common IBD-Associated Risk Alleles and Intestinal Permeability in a Cohort of Healthy First Degree Relatives of Individuals With Crohn's Disease (2013) (0)
- A35 GENOME WIDE ASSOCIATION STUDY OF ABNORMAL INTESTINAL PERMEABILITY IN HEALTHY FIRST DEGREE RELATIVES OF CROHN’S PATIENTS (2018) (0)
- Crohn's disease: we are in it for the long haul. Interview by Paul C Adams. (2008) (0)
- Probiotics in IBD: A Critical Review (2011) (0)
- Tu1454: THE SAFETY PROFILE OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS IN THE PHASE 3 U-ACHIEVE STUDY IS CONSISTENT WITH THAT IN APPROVED INDICATIONS (2022) (0)
- University of Birmingham Management of the pregnant inflammatory bowel disease patient on antitumour necrosis factor therapy (2016) (0)
- P661 Clinical response over 24 weeks for initial and delayed responders to induction therapy with risankizumab in Crohn’s disease: data from the ADVANCE and MOTIVATE studies (2023) (0)
- Physicians' perception of utility in Crohn's disease (1998) (0)
- Adalimumab Therapy maintains meaningful rates of steroid-free remission in patients with Crohnʼs Disease for up to 3 Years of Therapy: Results From an Open-Label Extension of CHARM: P-0117. (2009) (0)
- Sa1105 Delayed Timing of Post-Operative Colonoscopy Within 1 Year Does Not Predict a More Severe Rutgeerts Score (2016) (0)
- A91 UNMET NEEDS OF INFLAMMATORY BOWEL DISEASE PATIENTS IN CANADA: RESULTS OF A WEB SURVEY (2019) (0)
- Cumulative Incidence of Second Major Abdominal Surgery Crohnʼs Disease: A Systematic Review and Meta-analysis of Population-based Studies: 1741 (2013) (0)
- DOP42 Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials (2023) (0)
- S714 52-Week Risankizumab Subcutaneous Maintenance Dosing Is Efficacious and Well Tolerated in Patients With Moderate to Severe Crohn’s Disease Who Had Delayed Response to 12-Weeks IV Risankizumab Induction (2022) (0)
- A216 UC NARRATIVE CANADIAN DATA – COMPARING PATIENT AND PHYSICIAN PERSPECTIVES ON COMMUNICATION AND MANAGEMENT OF ULCERATIVE COLITIS (2019) (0)
- S935 Optimizing Access for Individuals With Suspected Inflammatory Bowel Disease Through the Development of a Triage Tool (2021) (0)
- Practical Deep Learning Tool For Scoring Of Ulcerative Colitis Disease Activity In Central Reading (2021) (0)
- P117 - Global safety of adalimumab in trials of patients with Crohn's disease (2009) (0)
- O30 Closure of perianal fistula in patients receiving ustekinumab in the SEAVUE and STARDUST trials (2022) (0)
- PWE-020 Corticosteroid Dose Reduction with Vedolizumab Treatment of Crohn’s Disease (2016) (0)
- Biologic Treatment of Crohn’s Disease: Adalimumab (2012) (0)
- A54 DIETARY COMPONENTS ARE ASSOCIATED WITH FECAL CALPROTECTIN IN ULCERATIVE COLITIS (2022) (0)
- A68 COST EFFECTIVENESS OF TIGHT CONTROL FOR CROHN’S DISEASE WITH ADALIMUMAB-BASED TREATMENT: ECONOMIC EVALUATION OF CALM TRIAL FROM CANADIAN PERSPECTIVE (2019) (0)
- 966: EFFICACY AND SAFETY OF EXTENDED INDUCTION TREATMENT WITH UPADACITINIB 45 MG ONCE DAILY FOLLOWED BY MAINTENANCE UPADACITINIB 15 OR 30 MG ONCE DAILY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (2022) (0)
- P548 Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn’s disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies (2023) (0)
- Artificial Intelligence(AI) In Endoscopy-Deep Learning for Scoring of Ulcerative Colitis Disease Activity Under Multiple Scoring Systems (2021) (0)
- 28: Monitoring Pediatric Inflammatory Bowel Disease – A Retrospective Analysis of Transabdominal Ultrasound (2015) (0)
- Su1298 Early Detection of Clostridium difficile Infection Impacts Disease Related Outcomes in Patients With Ulcerative Colitis Patients: A Population-Based Inception Cohort Study (2015) (0)
- Postoperative Mortality for the Inflammatory Bowel Diseases: A Systematic Review and Meta‐analysis of Population‐Based Studies: ACG Fellow Award: 2203 (2014) (0)
- P134 Point of care ultrasound accurately distinguishes inflammatory from non inflammatory disease in patients presenting with abdominal pain and diarrhea. (2017) (0)
- Weighted Gene Co-Expression Network Analysis Identifies a Functional Guild and Metabolite Cluster Mediating the Relationship between Mucosal Inflammation and Adherence to the Mediterranean Diet in Ulcerative Colitis (2023) (0)
- Mo1161 Accuracy of Point of Care Ultrasound Performed by Gastroenterologists in Patients Investigated for Symptoms of Diarrhea and Abdominal Pain (2014) (0)
- Are antibiotics useful in the treatment of IBD? (2008) (0)
- Sa1723 – Mucosal Healing Defined by Advanced Electronic Chromoendoscopy Picasso (Paddington International Virtual Chromoendoscopy Score) and Probe Confocal Laser Endomicroscopy Accurately Predict Histological Healing of Active Inflammation But Not Chronic Changes (2019) (0)
- Innovative Care for Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Use of Bedside Intestinal Ultrasound to Optimize Management (2022) (0)
- Methotrexate" "lessons from rheumatology". (2005) (0)
- Artificial Intelligence in Inflammatory Bowel Disease Endoscopy: Implications for Clinical Trials. (2023) (0)
- S740 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Final Results From the Phase 3 U-ACHIEVE Maintenance Study (2022) (0)
- Nutritional interventions in adult fibrostenotic Crohn’s disease: A systematic review (2023) (0)
- P212 Location and Kudo pit pattern reflect neoplastic histology of lesions detected at surveillance colonoscopy in inflammatory bowel disease. (2017) (0)
- GEOGRAPHIC DIFFERENCES IN THE RISK OF SURGERY IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS (2022) (0)
- P198 Practical deep learning tool for the scoring of ulcerative colitis disease activity in central reading (2021) (0)
- P463 Induction of endoscopic response: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis (2020) (0)
- The ultimate therapeutic goal: establishing and maintaining quality of life. (2004) (0)
- of Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease (2017) (0)
- S857 Patient-Reported Outcomes of Response and Remission Following Guselkumab Induction Treatment as Measured by the Inflammatory Bowel Disease Questionnaire: Results Through Week 12 of the Phase 2 GALAXI 1 Study (2021) (0)
- Item Content Validation for Two New Measures To Assess Crohnʼs Disease Patients’ Interest in Medication Change: 1019 (2007) (0)
- A173 INNOVATIVE CARE FOR INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC: USE OF BEDSIDE INTESTINAL ULTRASOUND TO OPTIMIZE MANAGEMENT (2021) (0)
- P703 Clinical, radiographic and endoscopic remission with vedolizumab treatment in Crohn’s disease (2018) (0)
- Cost-Effectiveness of Tight Control for Crohn’s Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective (2022) (0)
- S761 Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN Without a Clinical Response (2021) (0)
- Corrigendum to ‘Optimising monitoring in the management of Crohn's disease: A physician perspective’ [Journal of Crohn's and Colitis volume 7 (2013) 653–669] (2014) (0)
- O4 Multicentre prospective validation study of the paddington international virtual chromoendoscopy score (PICaSSO) in ulcerative colitis (2021) (0)
- Mo1931 – Urine Metabolomic Signatures Differentiate Pregnancy from the Non-Pregnant State and Differ in Pregnant Patients with Crohn’s Disease Compared with Ulcerative Colitis (2019) (0)
- Short-and Long-Term Efficacy of Adalimumab Following Infliximab Failure: Systematic Review and Meta-Analysis (2008) (0)
- A157 DEFINITIONS OF MEDITERRANEAN DIET INCONSISTENTLY ASSOCIATE WITH MARKERS OF GUT BARRIER FUNCTION OR SUBCLINICAL INFLAMMATION IN A POPULATION-BASED COHORT (2022) (0)
- A31 GLOBAL BURDEN OF HOSPITALIZATION FOR PERSONS WITH IBD IN THE 21ST CENTURY: TIME TREND ANALYSES (2019) (0)
- EP1287: EARLY SONOGRAPHIC RESPONSE AS A PREDICTOR OF RESPONSE TO ADALIMUMAB AT 6 MONTHS IN CROHN'S DISEASE: A PROSPECTIVE COHORT STUDY (2022) (0)
- Ustekinumab Is Effective for the Induction and Maintenance of Response in Crohnʼs Disease: A Multi-center Cohort Study: 641 (2016) (0)
- EFFICACY, SAFETY, AND TOLERABILITY OF NATALIZUMAB IN MAINTAINING CLINICAL RESPONSE AND REMISSION IN CROHNʼS DISEASE (ENACT-2): 788 (2004) (0)
- P053 Prolonged Therapy with MMX™ Mesalazine in Patients with Acute, Mild-to-Moderate Ulcerative Colitis Who Fail Initial Mesalazine Treatment may Avoid the Need for Therapeutic Escalation (2008) (0)
- Mo1742 Altered Prevalence of Circulating Novel Tc1, Tc17, Tcreg, and Double-Expressing CD8+ IFN-G+ IL-17+ T Cells in Inflammatory Bowel Disease Patients (2014) (0)
- 969: RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY (2022) (0)
- P671 An IL23R risk variant is associated with changes in CD4+ T-cell subsets in peripheral blood of Crohn's disease patients (2013) (0)
- P479 Reliability and responsiveness of histologic disease activity indices in Crohn’s Disease (2023) (0)
- Sa1556: GLOBAL HOSPITALIZATION TRENDS FOR FLARING CROHN'S DISEASE AND ULCERATIVE COLITIS: SYSTEMATIC REVIEW WITH TEMPORAL ANALYSES (2022) (0)
- Su2015 - Early 12 Week Ultrasound Response to Treatment, Used as a Predictor of Response at 6 Months in Crohn's Disease: A Prospective Cohort Study (2018) (0)
- P507 United States and European patient perspectives on the impact of moderate-to-severe Ulcerative Colitis on sexual activity: Communicating Needs and Features of IBD Experiences (CONFIDE) survey (2023) (0)
- Su483 SERUM PROTEOMICS IDENTIFIES UNIQUE SIGNATURE TO DIFFERENTIATE FIBROSTENOTIC AND INFLAMMATORY CROHN'S DISEASE. (2021) (0)
- Location and Kudo Pit Pattern Reflect Neoplastic Histology of Lesions Detected at Surveillance Colonoscopy in Inflammatory Bowel Disease (2017) (0)
- TOUCH™ Study Patient Outcomes: The Impact of Natalizumab on Crohn's Disease Severity: 1139 (2009) (0)
- 1076 A Simple, Validated Ultrasonographic Score for the Detection of Inflammation in Established Crohn's Disease (2016) (0)
- A146 DIETARY INTAKE OF PATIENTS WITH CROHN’S DISEASE IN REMISSION: A CROSS-SECTIONAL STUDY (2018) (0)
- TOUCH® Patient Reported Outcomes Study: The Impact of Natalizumab on Crohn's Disease Severity: P‐63 (2012) (0)
- Tu1251: INCIDENCE AND PREVALENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES (2022) (0)
- Declining Corticosteroid Use for Inflammatory Bowel Disease Across Alberta: A Population-Based Cohort Study (2022) (0)
- VALIDATION OF A NEW OPTICAL DIAGNOSIS TRAINING PLATFORM TO IMPROVE DYSPLASIA CHARACTERISATION IN INFLAMMATORY BOWEL DISEASE (OPTIC-IBD): A MULTICENTRE RANDOMISED CONTROLLED STUDY (2022) (0)
- Deep Remission With Vedolizumab in Patients With Ulcerative Colitis: Evaluating Various Combinations of Endoscopic and Patient-Reported Outcomes: 1629 (2014) (0)
- P381 Adalimumab efficacy and safety by disease duration: analysis of pooled studies of Crohn's disease. (2017) (0)
- Tu1268 Effect of Vedolizumab on Health-Related Quality of Life in Patients With Crohn's Disease (2015) (0)
- Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis (2023) (0)
- Does Multi-Drug Crohnʼs Therapy Result in Improved Patient Outcomes?: 1028 (2008) (0)
- 1074 The Concordance Between Disease Activity and Prevalence of Th1 Subsets in Patients With Inflammatory Bowel Disease (2016) (0)
- Response Rates in the Control Arms of Randomized Controlled Trials: A Systematic Review and Meta-analysis of Trials on Monoclonal Antibodies in Ulcerative Colitis: 1846 (2013) (0)
- S810 Efficacy Outcomes by Symptom-Based Response Status After Induction: Week-48 Results from the GALAXI 1 Trial of Guselkumab in Crohn’s Disease (2022) (0)
- P364 Resected fibrostenotic intestine from Crohn's disease patients express significant TNF in proliferative fibroblasts and in extracellular matrix (2014) (0)
- Benefit-Risk Assessment of the TNF-Antagonists Adalimumab and Certolizumab Pegol for Maintenance Treatment of Crohn's Disease (2011) (0)
- P457 Biological interventions for induction and maintenance of mucosal healing in ulcerative colitis: A Cochrane systematic review (2018) (0)
- P571 Adalimumab maintains remission for up to 4 years in patients with ulcerative colitis (2014) (0)
- P240 CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn’s disease: Data from the CALM study (2020) (0)
- Tu1525 Sessile Serrated Adenomas Are Common in IBD Surveillance Colonoscopy and Better Detected by Chromoendoscopy and Virtual Chromoendoscopy (2014) (0)
- A186 ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION (2022) (0)
- Mo1227 Clinical Decision Making in Inflammatory Bowel Disease: A Prospective Study to Evaluate Use of Point of Care Ultrasound (2013) (0)
- Tu1933 Fecal Calprotectin Improves the Predictive Power of 3 Practical Indices for Mucosal Healing Among Patients With Crohn's Disease: Results From PREDICT (2016) (0)
- Mo1843 – A Significant Decline in Colectomy Rates for Colorectal Cancer in Patients with Ulcerative Colitis (2019) (0)
- A18 DIETARY PREDICTORS OF BIOLOGICAL ACTIVITY IN CROHN’S DISEASE: A RETROSPECTIVE COHORT STUDY (2021) (0)
- ENACT-2 SAFETY, TOLERABILITY, AND IMMUNOGENICITY RESULTS OF NATALIZUMAB IN PATIENTS WITH CROHNʼS DISEASE: 827 (2004) (0)
- Quality of life improvements with Natalizumab maintenance therapy in patients exposed to or failing TNF-alpha inhibitor therapy in the ENACT-2 Trial: P-0051. (2008) (0)
- Mo1202 Characterization of Anti-Tumor Necrosis Factor Agent-Induced Lupus in Patients With Inflammatory Bowel Disease (2014) (0)
- S744 Risankizumab Induction Therapy Provides Early Symptom Improvements in Abdominal Pain and Stool Frequency in Patients With Moderate to Severe Crohn’s Disease: Results From Two Phase 3 Induction Studies (2021) (0)
- A79 FECAL SHORT CHAIN FATTY ACID COMPOSITION IN CROHN’S DISEASE PATIENTS CONSUMING A DIVERSIFIED COMPARED TO NON-DIVERSIFIED DIET (2018) (0)
- PYRAMID Registry: Long-term Safety of Adalimumab by Age in Patients With Crohnʼs Disease: 717 (2017) (0)
- Tu1438: LONG-TERM SAFETY OF USTEKINUMAB IN IBD PATIENTS WITH A HISTORY OF BIOLOGIC FAILURE: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CROHN'S DISEASE AND 2 YEARS IN ULCERATIVE COLITIS (2022) (0)
- C-Reactive Protein and Erythrocyte Sedimentation Rate Do Not Correlate With Disease Activity in Pregnant Women With IBD: 1744 (2014) (0)
- A210 THE BURDEN OF IBD HOSPITALIZATION IN CANADA: AN ASSESSMENT OF THE CURRENT AND FUTURE BURDEN IN A NATION-WIDE ANALYSIS (2023) (0)
- Sa1254 Biologic Therapies Are Effective in Inducing and Maintaining Mucosal Healing in Ulcerative Colitis: A Systematic Review & Meta-Analysis (2015) (0)
- Sa2028 Inter-Observer Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease (2016) (0)
- Steroid-Free remission in response to Adalimumab therapy over 2 years in patients with Crohnʼs Disease: Results From open-label extension of the CHARM trial: P-0075. (2008) (0)
- Customized Use of Anti-Tumour Necrosis Factor-α Therapy During Pregnancy. (2018) (0)
- 876 Use of Contrast Enhanced Transabdominal Ultrasound in the Prospective Evaluation of Crohn's Disease: Contrast Enhancement Responsiveness and Nonresponse to Treatment With Adalimumab (2014) (0)
- 474 - Exploring Stoma Rates in Crohn's Disease in the Biologic Era: A Population-Based Time Trend Analysis (2018) (0)
- Publisher Correction: Crohn’s disease (2020) (0)
- P268 Development and validation of a novel composite index for the assessment of endoscopic and histologic disease activity in pouchitis: The Atlantic pouchitis index (2023) (0)
- Sa1200 Predictors of 3-Year Risk of Colectomy Among Hospitalized Patients With Ulcerative Colitis: A Population-Based Study (2015) (0)
- VALIDATION OF A NEW OPTICAL DIAGNOSIS TRAINING PLATFORM TO IMPROVE DYSPLASIA CHARACTERIZATION IN INFLAMMATORY BOWEL DISEASE (OPTIC-IBD): A MULTICENTER RANDOMIZED CONTROLLED STUDY (2022) (0)
- Predicting Postoperative Mortality from Comorbidity Indices in Administrative Databases Among Inflammatory Bowel Disease Patients: 1142 (2008) (0)
- S927 The Impact of the COVID-19 Pandemic on Patients With Ulcerative Colitis: Results From a Global Ulcerative Colitis Patient Survey (2022) (0)
- The Real-World Global Use of Patient-Reported Outcomes for the Care of Patients With Inflammatory Bowel Disease (2023) (0)
- Application of Deep Learning Models to Improve Ulcerative Colitis Endoscopic Disease Activity Scoring Under Multiple Scoring Systems. (2022) (0)
- The Impact of the COVID-19 Pandemic on IBD Care in Alberta: Patient and Provider Perspectives (2022) (0)
- Sa1255 The Comparative Efficacy of Induction of Remission for Mesalamine, Sulfasalazine, and Budesonide for the Treatment of Mild to Moderate Crohn's Disease: A Bayesian Network Meta-Analysis (2015) (0)
- 888: EFFICACY AND SAFETY OF GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY (2022) (0)
- Patient and Physician Perceptions on Living with Ulcerative Colitis: Results from Two Internet Surveys: 994 (2007) (0)
- The in-Vitro Effect of Cigarette Smoke Extract on Monocyte-Derived Dendritic Cell Phenotypes is Different in Crohn's Disease Compared With Ulcerative Colitis Patients (2011) (0)
- A150 ACCESS TIMES TO GASTROENTEROLOGY FOR HIGH-RISK IBD REFERRALS IN THE GREATER CALGARY REGION (2020) (0)
- Effect of Adalimumab dose Escalation on Clinical, Health-Related Quality of Life, Treatment Satisfaction and Work Productivity Outcomes Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada (2017) (0)
- Patients with Ulcerative Colitis Taking Asacol have 1000-Fold Higher Levels of Dibutyl Phthalate as Compared to Mezavant or Salofalk (2017) (0)
- DOP40 Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib (2023) (0)
- University of Birmingham Ulcerative colitis-associated hospitalization costs (2016) (0)
- 1140 PATIENTS WITH INFLAMMATORY BOWEL DISEASE ARE FREQUENTLY PRESCRIBED OPIOID ANALGESICS WHEN DISCHARGED FROM THE EMERGENCY DEPARTMENT (2020) (0)
- Mo1780 – Gender Bias in Referral and Diagnosis of Inflammatory Bowel Disease in a Canadian Inception Cohort (2019) (0)
- Sa1763 1,25-Dihydroxyvitamin D3 Decreases Th1 and Tc1 Lymphocytes From the Peripheral Blood of IBD Patients and Healthy Controls Ex Vivo but Has No Effect on IL-17 or FoxP3 Expression (2015) (0)
- Biological therapy in Crohn's disease: is it an issue of how hard you strike or how fast you strike? (2009) (0)
- A195 DURABILITY OF SEROLOGICAL RESPONSES AFTER SECOND, THIRD AND FOURTH DOSE OF SARS-COV-2 VACCINATION IN INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY (2023) (0)
- Pregnant Women with Inflammatory Bowel Disease (IBD) are at Significantly Increased Risk of Vitamin D Insufficiency (2017) (0)
- Tu1310 Treatment of Infliximab or Adalimumab Induces Suppression of Circulating CD45ROHigh CD4+ T-Cells in Crohn's Disease Patients After 4 Weeks of Drug Administration (2015) (0)
- Sa1877 Decreased TGF-ß1 Secretion From Monocyte-Derived Dendritic Cells is Associated With Higher Frequency of IL-17 Secreting FOXP3+ CD4+ T Cells in Peripheral Blood From Inflammatory Bowel Disease Patients (2012) (0)
- The race to block TNF-alpha: the caution flag is raised again. (2004) (0)
- 793: ENVIRONMENTAL FACTORS ASSOCIATED WITH RISK OF CROHN'S DISEASE DEVELOPMENT IN A PROSPECTIVE COHORT OF HEALTHY FIRST-DEGREE RELATIVES OF CD PATIENTS (2022) (0)
- T1720 Regulation of the Pro-Resolution Mediators Prostaglandin D2 and Lipoxin A4 in Quiescent Human Colitis (2009) (0)
- P003 - The ACCESS trial: impact of adalimumab on steroid-free remission and fistula closure in patients with Crohn's disease (2009) (0)
- Risk-benefit Assessment of Adalimumab and Certolizumab Pegol as Induction Treatment for Crohnʼs Disease: 1235 (2011) (0)
- The Simple Pediatric Activity Ultrasound Score (SPAUSS) for the Accurate Detection of Pediatric Inflammatory Bowel Disease (2017) (0)
- S820 Health Disparities, Social Determinants of Health, and Emotional Impacts in Patients With Ulcerative Colitis: Results From a Global Ulcerative Colitis Patient Survey (2022) (0)
- Health-related quality of life in Crohn's disease: Whose preferences should we use? (2000) (0)
- P719 Symptomatic improvement and long-term stability of ulcerative colitis symptoms over 3 years of ozanimod treatment (2023) (0)
- Mo1729 Mucosal Gene Expression Patterns From Inflamed Intestine May Distinguish Newly Diagnosed IBD From Established IBD (2015) (0)
- P464 Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis (2023) (0)
- Long-Term Safety of Adalimumab in Clinical Trials in Adult Patients With Crohnʼs Disease or Ulcerative Colitis: 1858 (2015) (0)
- Clostridium difficile Infection in Ulcerative Colitis: Increased Risk of Colectomy and Postoperative Infectious Complications: 1266 (2011) (0)
- A4 PREDNISOLONE, A GLUCOCORTICOID WIDELY USED FOR TREATMENT OF IBD, ENHANCES A HUMAN INTERLEUKIN-4-ACTIVATED MACROPHAGE PHENOTYPE (2023) (0)
- P550 Early 12-week ultrasound response to treatment, used as a predictor of response at 6 months in Crohn’s disease: A prospective cohort study (2018) (0)
- TOUCH® Patient Reported Outcomes Study: The Impact of Natalizumab on Common Measures of Quality of Life in CD patients: P‐64 (2012) (0)
- S739 Matching-Adjusted Indirect Comparison of Upadacitinib versus Vedolizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis (2022) (0)
- P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison (2023) (0)
- S37 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results (2022) (0)
- Mo1296 Quality of Life for Patients With Deep Remission vs. Clinical Remission and Deep Remission vs. Absence of Mucosal Ulceration: 3-Year Data From CHARM/ADHERE (2013) (0)
- Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials (2020) (0)
- THE FIRST REAL-LIFE MULTICENTRE, PROSPECTIVE VALIDATION STUDY OF THE ELECTRONIC CHROMOENDOSCOPY SCORING SYSTEM (PICASSO-THE PADDINGTON INTERNATIONAL VIRTUAL CHROMOENDOSCOPY SCORE) AND ITS OUTCOME IN ULCERATIVE COLITIS (2020) (0)
- P365 Biological interventions for induction and maintenance of mucosal healing in Crohn’s disease: A Cochrane systematic review (2018) (0)
- Sa1777 Novel Regulatory T Cell Population Co-Expressing Ror γT+ or GATA3+ Is Increased in Intestinal Lamina Propria of IBD Patients (2014) (0)
- DOP90 The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab (2023) (0)
- Artificial Intelligence enabled histological prediction of remission or activity and clinical outcomes in ulcerative colitis. (2023) (0)
- Crohn’s Disease: We are in it for the Long Haul (2008) (0)
- P425 The utility of intestinal ultrasound to inform clinical decision making (2023) (0)
- management of the pregnant inflammatory bowel disease patient on antitumour necrosis factor therapy: state of the art and future directions Management of the inflammatory bowel disease patient on antitumour necrosis factor therapy: State of the art and future directions. (2014) (0)
- A190 THE IMPACT OF BOWEL URGENCY ON THE LIVES OF PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY (2022) (0)
- KEEP CALM AND TREAT TO TARGET IN INFLAMMATORY BOWEL DISEASE This symposium took place on 30 th October 2017 , as part of the 25 th United European Gastroenterology ( UEG ) Week in Barcelona , Spain (2017) (0)
- A124 IMPROVEMENT IN DISEASE ACTIVITY IS ASSOCIATED WITH LESS DISABILITY IN A PROSPECTIVE STUDY OF PEDIATRIC TRANSITION PATIENTS WITH IBD (2019) (0)
- Combining Patient Preferences and Comparative Effectiveness Research to Inform Treatment Approaches for Maintenance Therapy in Crohn’s Disease (2017) (0)
- Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases. (2022) (0)
- 76 Surgical Resection Rates for Crohn's Disease Are Decreasing: A Population-Based Time Trend Analysis (2016) (0)
- PTH-027 Location and kudo pit pattern reflect neoplastic histology of lesions detected at surveillance colonoscopy in inflammatory bowel disease (2017) (0)
- University of Birmingham Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease (2018) (0)
- Adalimumab Therapy maintains remission for up to 3 Years in patients with moderately to severely active Crohnʼs Disease: Results From an Open-Label Extension of CHARM: P-0121. (2009) (0)
- Su1325 Women With Inflammatory Bowel Disease Are At Higher Risk of Gestational Diabetes: A Novel Finding (2014) (0)
- A35 FORECASTING THE INCIDENCE AND PREVALENCE OF INFLAMMATORY BOWEL DISEASE: A CANADIAN NATION-WIDE ANALYSIS (2023) (0)
- A108 USTEKINUMAB IS EFFECTIVE FOR INDUCING CLINICAL, ENDOSCOPIC, AND RADIOGRAPHIC RESPONSE IN REFRACTORY MODERATE-TO-SEVERE CROHN’S DISEASE: A MULTICENTRE COHORT STUDY (2018) (0)
- REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis (2022) (0)
- The Biosimilar Revolution: Coming to an IBD Patient Near You? (2017) (0)
- A236 ASSOCIATION OF STOOL METABOLOMIC PROFILE AND MICROBIOME COMPOSITION RISK SCORE WITH FUTURE ONSET OF CROHN’S DISEASE (2022) (0)
- P104 Assessments from a Patient Survey on the Impact of Ulcerative Colitis on Patients' Lives: A Comparison with Other Chronic Diseases (2008) (0)
- Sa1884 – Unmet Need of Inflammatory Bowel Disease in Canada: Results of a Patient Survey (2019) (0)
- Induction Treatment with Anti-TNF Decreases C-Reactive Protein Levels among Crohnʼs Disease Patients: A Systematic Review and Meta-analysis: 1790 (2013) (0)
- A192 EFFICACY OF USTEKINUMAB IN SMALL BOWEL STRICTURES OF FIBROSTENOTIC CROHN'S DISEASE AS ASSESSED BY INTESTINAL ULTRASOUND (2023) (0)
- A97 DEVELOPMENT OF PREDICTION MODELS FOR THE TRIAGING OF REFERRALS OF INDIVIDUALS WITH SUSPECTED INFLAMMATORY BOWEL DISEASE TO IMPROVE PROMPT ACCESS TO CARE (2022) (0)
- A116 LOSS OF RESPONSE TO VEDOLIZUMAB MAINTENANCE THERAPY IN CROHN`S DISEASE (2018) (0)
- A158 COMPARING CORTIMENT® AND PREDNISONE IN ULCERTATIVE COLITIS: A POPULATION-BASED STUDY OF OUTCOMES (2021) (0)
- A Cost-Utility Analysis of Smoking Cessation Programs for Patients with Crohnʼs Disease: 1738 (2013) (0)
- Sa1808 - Long-Term Effectiveness and Safety of Adalimumab Based on Crohn's Disease Duration: Results from the Pyramid Registry (2018) (0)
- Meta‐analysis: Placebo rates in microscopic colitis randomised trials and applications for future drug development using a historical control arm (2023) (0)
- 711 CLINICAL OUTCOMES FOLLOWING ENDO-HISTOLOGIC REMISSION IN ULCERATIVE COLITIS ASSESSED BY ELECTRONIC CHROMOENDOSCOPY USING PICASSO SCORE IS NOT SUPERIOR TO ENDOSCOPY OR HISTOLOGY ALONE (2021) (0)
- Sa1557: FORECASTING THE INCIDENCE AND PREVALENCE OF IBD: A CANADIAN NATION-WIDE ANALYSIS (2022) (0)
- 135 THE GEM PROJECT: DIETARY PATTERNS ARE ASSOCIATED WITH MICROBIOME COMPOSITION AND INTESTINAL INFLAMMATION IN HEALHY FIRST-DEGREE RELATIVES OF CROHN'S DISEASE PATIENTS (2020) (0)
- A87 HEALTHCARE PROVIDER SATISFACTION WITH VIRTUAL CARE DELIVERY IN ALBERTA DURING THE COVID-19 PANDEMIC. (2021) (0)
- Gut bacteria linked to Inflammatory Bowel Disease (2012) (0)
- S972 The Real World Global Use of Patient-Reported Outcomes (PROs) for the Care of Patients With IBD (2022) (0)
- S732 Ozanimod Is an Effective Oral Treatment for Patients With Ulcerative Colitis Regardless of Moderate orSevere Endoscopic Disease Activity at Baseline: A Post Hoc Analysis of the Phase 3 True North Study (2022) (0)
- P174 Defining Crohn’s Disease Strictures Using Intestinal Ultrasound Compared to Histopathology (2021) (0)
- Tu1919 Phthalate Levels are Higher in Patients With Ulcerative Colitis Taking Asacol as Compared to Mezavant: A Comparative Safety Analysis (2016) (0)
- The Classical Immunosuppression : Overrated or Underused ? Deep Remission : A New Concept ? (2013) (0)
- Exposing the Weaknesses: A Systematic Review of Azathioprine Efficacy in Ulcerative Colitis: 931 (2007) (0)
- Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions. (2023) (0)
- Medical induction of active Crohnʼs ileitis: Evidence-based management (2008) (0)
- Su1783 – Rates of Treatment Ineffectiveness After Initiating Anti-TNF Therapy: Results of a Pooled Population Based Interprovincial Analysis (2019) (0)
- Dietary Intake of Patients with Crohn's Disease in Remission: A Single Center Experience (2017) (0)
- A63 HOSPITALIZATION RATES FOR INFLAMMATORY BOWEL DISEASE VARY GEOGRAPHICALLY IN SOUTHERN ALBERTA: A POPULATION-BASED COHORT STUDY (2020) (0)
- The Great Debate With IBD Biosimilars (2021) (0)
- PYRAMID Registry: Observational Study of Adalimumab in Crohnʼs Disease at Year 2: 1183 (2010) (0)
- Fr098 IMPACT OF COVID-19 PANDEMIC IN IBD PATIENT CARE (2021) (0)
- Sa1774 Cigarette Smoke Extract Decreases Regulatory T-Cells and Increases IFN-Gamma Secreting T-Cells in Peripheral Blood From Crohn's Disease Compared to Ulcerative Colitis Patients: Differential Smoking Effects on Two Types of Inflammatory Bowel Disease (2013) (0)
- 678 Efficacy of Upadacitinib as an Induction Therapy in Severe and Refractory Ulcerative Colitis: Sub-Group Analysis of the Phase 2b Study U-ACHIEVE (2019) (0)
- 715 Corticosteroid Sparing Effects of Ustekinumab Therapy in UC Patients: Results From the UNIFI Program (2019) (0)
- Anti-Indigenous bias of medical school applicants: a cross-sectional study (2022) (0)
- Mo1868 EFFICACY AND SAFETY OF SIMULTANEOUS TREATMENT WITH TWO BIOLOGIC MEDICATIONS IN REFRACTORY CROHN'S DISEASE (2020) (0)
- Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data. (2023) (0)
- P131 Serum Proteomics and Intestinal Ultrasound Differentiates Fibrostenotic and Inflammatory Crohn’s Disease (2021) (0)
- Mo1160 Accuracy of Gastroenterologist Performed Point of Care Transabdominal Ultrasound in Detection of Crohn's Disease Activity (2014) (0)
- P179 Comparative benefit-risk profile of induction and maintenance therapy with upadacitinib versus placebo in patients with moderately to severely active ulcerative colitis (2023) (0)
- A193 DEMOGRAPHIC, SOCIAL AND OCCUPATIONAL FACTORS THAT PREVENTED EXPOSURE TO SARS-COV-2 IN INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC: A PROSPECTIVE COHORT STUDY (2023) (0)
- Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis: 1614 (2012) (0)
- Mo1090 The Costs of Care for Patients With Ulcerative Colitis: Effect of Adalimumab on Health Care Resources Utilisation in Clinical Practice From INSPIRADA (2016) (0)
- DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study (2023) (0)
- Sa1782 Peripheral Blood CD4+ T-Lymphocytes From Crohn's Disease Patients Demonstrate Hyper-Responses to PRO-Inflammatory Cytokines In Vitro by Generating IL-17/FOXP3 Double Expressing Sub-Population (2013) (0)
- Hospitalization Rates in Patients with Crohnʼs Disease and Deep Remission: Data from the 56-week CHARM Trial: 1813 (2013) (0)
- P070 Perceptions of Living with Ulcerative Colitis: Results from Two Internet Surveys, Conducted in Patients and Physicians (2008) (0)
- Mo1729 Differential Effect of Cigarette Smoke Extract Modifies CD103 and CXCR3 Expressions of Monocyte-Derived Dendritic Cells From Crohn's Disease and Ulcerative Colitis Patients (2014) (0)
- TOUCH™ Study Patient Outcomes: The Impact of Natalizumab on Common Measures of Quality of Life in CD patients: 1135 (2009) (0)
- Cross-Sectional Analysis of Overall Dietary Intake and Mediterranean Dietary Pattern in Patient’s with Crohn’s Disease (2018) (0)
- S1004 Adverse Events and Serological Responses Following SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease (2022) (0)
- S696 Efficacy of Ustekinumab for Ulcerative Colitis in Patients Through 3 Years: UNIFI Long-term Extension (2021) (0)
- P-139 PYRAMID Registry: An Observational Study of Adalimumab in Crohn's Disease: Results at Year 5 (2013) (0)
- Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn’s disease highlight earliest events of pathogenesis (2023) (0)
- Colorectal Neoplasia Surveillance in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: An Economic Evaluation: 2100 (2013) (0)
- P329 Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA. (2017) (0)
- P669 Adalimumab long-term effectiveness in adalimumab-naïve patients with Crohn's disease: final data from PYRAMID registry. (2017) (0)
- S777 Benefit–Risk Assessment of Upadacitinib Treatment in Patients With Moderately to Severely Active Ulcerative Colitis (2022) (0)
- P658 Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison (2023) (0)
- P286 Assessing preference for deep remission in patients with Crohn's disease (2012) (0)
- A92 PREVIOUS VIRTUAL CONSULTATION EXPERIENCE IS RELATED TO PRECEPTOR’S WILLINGNESS TO INVOLVE TRAINEES IN VIRTUAL CARE DURING THE COVID-19 PANDEMIC (2021) (0)
- DOP018 Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA. (2017) (0)
- Su1309 The Age Dependent Effect of Smoking on the Risk of Surgery for the Inflammatory Bowel Diseases (2015) (0)
- Correction: Comparison between non-pulmonary and pulmonary immune responses in a HIV decedent who succumbed to COVID-19 (2022) (0)
- S1235 Two New Clinical Assessment Tools for Crohn's Disease Patients: Validation, Sensitivity, and Specificity (2008) (0)
- Fr099 HEALTHCARE PROVIDER SATISFACTION WITH VIRTUAL CARE DELIVERY IN ALBERTA DURING THE COVID-19 PANDEMIC. (2021) (0)
- Mo1079: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: IMPACT OF ULCERATIVE COLITIS SYMPTOMS ON HEALTH CARE PROFESSIONAL TREATMENT DECISIONS (2022) (0)
- 968: TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTEGRATED SUMMARY OF SAFETY DATA FROM THE GLOBAL OCTAVE AND RIVETING CLINICAL TRIALS (2022) (0)
- Tu1451: ACHIEVEMENT OF STEROID-FREE REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE DURING TREATMENT WITH RISANKIZUMAB (2022) (0)
- P433 Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease (2023) (0)
- Quality-of-Life and Work Productivity Outcomes with Adalimumab for Patients Previously Treated with High-Dose Infliximab for Crohnʼs Disease: 1192 (2010) (0)
- A170 ADVERSE EVENTS & SEROLOGICAL RESPONSES FOLLOWING SARS-COV-2 VACCINATION IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE (2023) (0)
- A169 THE DIRECT COSTS OF INFLAMMATORY BOWEL DISEASE IN CANADA: A POPULATION-BASED ANALYSIS OF HISTORICAL AND CURRENT COSTS (2023) (0)
- A73 CANADIAN INFLAMMATORY BOWEL DISEASE MOBILE APPS: CURRENT LANDSCAPE AND NEEDS (2022) (0)
- P273 Colonic confocal laser endomicroscopy findings in patients with primary sclerosing cholangitis (2013) (0)
- A225 QUANTIFICATION OF BONE DENSITY AND DIETARY RISK FACTORS FOR BONE FRAGILITY IN INFLAMMATORY BOWEL DISEASE (2023) (0)
- P603 Paediatric onset inflammatory bowel disease is not associated with more disability compared with adult onset disease (2019) (0)
- The Impact of Ulcerative Colitis on Patients’ Lives Compared with Other Chronic Diseases: A Patient Survey: 992 (2007) (0)
- PWE-260 Optimal C reactive protein cut-off point for predicting hospitalisation in patients with moderately active Crohn's disease (2012) (0)
- Sa1267 Fibrostenotic Disease Behavior at the Onset of Biologic Therapy is a Predictor of Poor Outcomes (2012) (0)
- P-050 High Rates of Steroid Dependence Amongst IBD Patients: Results of a Health Claims Database Analysis (2013) (0)
- University of Birmingham Transperineal ultrasonography in perianal Crohn disease (2016) (0)
- P028 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Experience of Ulcerative Colitis Symptoms (2021) (0)
- SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY (2022) (0)
- TOUCH™ Study Patient Outcomes: The Impact of Natalizumab on Utilization of Healthcare Resources by the Patients and Their Associated Treatment Satisfaction: 1130 (2009) (0)
- A180 PLACEBO RATES IN MICROSCOPIC COLITIS RANDOMIZED TRIALS: APPLICATIONS FOR FUTURE DRUG DEVELOPMENT USING A HISTORICAL CONTROL ARM (2023) (0)
- Tu1445: EFFECT OF PHARMACOKINETICS AND IMMUNOGENICITY ON CLINICAL AND ENDOSCOPIC EFFICACY IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SEAVUE STUDY (2022) (0)
- P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial (2023) (0)
- A106 USTEKINUMAB IS EFFECTIVE FOR MAINTAINING CLINICAL RESPONSE IN REFRACTORY MODERATE-TO-SEVERE CROHN’S DISEASE: A MULTICENTRE COHORT STUDY (2018) (0)
- Prolonged MMX® mesalazine therapy in patients with acute, mild-to-moderate ulcerative colitis who fail initial mesalazine treatment may prevent a requirement for therapeutic escalation (2010) (0)
- Sa1754 - Biological Interventions for Induction and Maintenance of Mucosal Healing in Ulcerative Colitis: A Cochrane Systematic Review (2018) (0)
- P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension (2023) (0)
- Tu1449: EFFICACY AND SAFETY OF ADVANCED INDUCTION AND MAINTENANCE THERAPIES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INDIRECT TREATMENT COMPARISON USING BAYESIAN NETWORK META-ANALYSIS (2022) (0)
- A122 COMBINATION BIOLOGIC THERAPY IN INFLAMMATORY BOWEL DISEASE: THE CALGARY EXPERIENCE (2019) (0)
- Mo1895 – Efficacy of Intravenous Ustekinumab Re-Induction in Patients with Crohn’s Disease with a Loss of Response (2019) (0)
- A118 UPPER GASTROINTESTINAL HEMORRHAGE SECONDARY TO SUPERIOR MESENTERIC ARTERY PSEUDOANEURYSM: CASE REPORT AND REVIEW OF LITERATURE (2022) (0)
- P023 PATIENT AND HEALTHCARE PROFESSIONAL VIEWS ON EMOTIONAL HEALTH AND INTIMACY IN ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY (2019) (0)
- Su1513: IMPACT OF MODERATE-TO-SEVERE ENDOSCOPIC DISEASE CRITERIA ON ENDOSCOPIC RESPONSE, ENDOSCOPIC REMISSION, AND DEEP REMISSION IN PATIENTS RECEIVING USTEKINUMAB OR ADALIMUMAB IN THE SEAVUE STUDY (2022) (0)
- S759 Efficacy and Safety of Mirikizumab in Patients With Ulcerative Colitis: 104-Week Results From a Phase 2 Randomized Controlled Trial (2021) (0)
- Mo1097 Adalimumab Improves Treatment Satisfaction With Medication and Work Productivity Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From INSPIRADA (2016) (0)
- OP29 Peri-natal exposure to parental Crohn’s disease is associated with impaired gut barrier, microbiome composition differences and increased risk of Crohn’s disease (2023) (0)
- Prevalence of extraintestinal manifestations and autoimmune disorders in patients with familial and sporadic inflammatory bowel diseasehten (2000) (0)
- S1038 Factors Influencing Workforce Participation and Productivity Among Crohn's Disease Patients (2009) (0)
- P164 Mucosal healing (MH) assessed with PICaSSO (Paddington International Virtual ChromoendoScopy ScOre) and probe Confocal Laser Endomicroscopy (pCLE) do not reflect histological normalisation using the ECAP (Extent Chronicity Activity Plus) score (2019) (0)
- S1056 Medical Management of Inflammatory Bowel Disease; Patterns of Infliximab Use Amongst Canadian Gastroenterologists (2008) (0)
- The Interaction Between NOD2 and Smoking Is Specific to the 1007fs SNP of the NOD2 Gene in Crohnʼs Disease: A Systematic Review and Meta-analysis: 1979 (2015) (0)
- P341 Induction of response and remission: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis (2020) (0)
- TOUCH™ Study Patient Outcomes: Workforce Participation, Productivity and the Impact of Natalizumab: 1134 (2009) (0)
- The race to block TNF‐α: The caution flag is raised again (2004) (0)
- TOUCH® PRO Study: The Impact of Natalizumab on Utilization of Healthcare Resources by the Patients and Their Associated Treatment Satisfaction: P‐65 (2012) (0)
- Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study. (2023) (0)
- A216 BOWEL URGENCY COMMUNICATION GAP BETWEEN HEALTH CARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY (2023) (0)
- 114 - EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U- ENDURE MAINTENANCE STUDY (2023) (0)
- P13 Communicating needs and features of IBD experiences (CONFIDE) survey: patient and health care professional perspectives (2022) (0)
- P899 Analysis of IL-23 receptor genetic variants associations with gut microbiome composition and barrier function in a cohort of healthy first-degree relatives of subjects with Crohn's disease (2023) (0)
- Novel concepts in in fl ammatory bowel disease (2014) (0)
- Letter: combination of biologics in inflammatory bowel diseases. Authors' reply (2020) (0)
- University of Birmingham Cross-sectional analysis of overall dietary intake and Mediterranean dietary pattern in patients with crohn's disease (2018) (0)
- Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database [Erratum] (2018) (0)
- Su1323 Patients With Crohn's Disease Who Never Smoke Are More Likely to Carry NOD2 Variants: A Case-Only NOD2-Smoking Interaction Study (2015) (0)
- Non-Hospitalized 1 Ulcerative Colitis : The Toronto Consensus 2 3 (2015) (0)
- Sa1625: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: EXPERIENCE OF BOWEL URGENCY FOR PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS (2022) (0)
- A133 PEDIATRIC ONSET INFLAMMATORY BOWEL DISEASE IS NOT ASSOCIATED WITH MORE DISABILITY COMPARED TO ADULT ONSET DISEASE. (2019) (0)
- Su1912 CDEIS SCORE OF 2 IS OPTIMAL CUT-OFF ASSOCIATED WITH LOWER RISK OF DISEASE PROGRESSION IN EARLY CROHN'S DISEASE: DATA FROM THE CALM STUDY (2020) (0)
- Development of Three Practical Indices for Mucosal Healing Among Patients With Moderate to Severe Crohn's Disease: P‐59 (2012) (0)
- Pyramid Registry: An Observational Study of Adalimumab in Crohnʼs Disease: Results at Year Five: 1682 (2013) (0)
- Adalimumab for the treatment of Crohn's disease. (2008) (0)
- 654: A THIRD DOSE OF SARS-COV-2 VACCINE YIELDS HIGH ANTIBODY LEVELS COMPARED TO TWO DOSE VACCINATION SCHEDULE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (2022) (0)
- A13 PROTEINS AND FIBROSTENOTIC CROHN’S DISEASE; WHO SHOWED UP TO THE PARTY? (2019) (0)
- Su1484: SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY (2022) (0)
- A SIMPLE ULTRASOUND SCORE FOR THE ACCURATE DETECTION AND MONITORING OF PEDIATRIC INFLAMMATORY BOWEL DISEASE (2017) (0)
- OP15 Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extension (2023) (0)
- Sa1758 In Vitro Adalimumab Exposure Decreases RORγT Expressing and RORγT/FoxP3 Double Expressing T-Lymphocytes From Peripheral Blood of Crohn's Disease Patients: A Study of Th17 Plasticity in Response to Anti-TNF (2015) (0)
- Su1203 Lamina Propria T Helper Cell Subsets Distinguish Between Ulcerative Colitis and Crohn's Disease (2015) (0)
- Sa1583: SERUM PROTEOMIC MARKERS THAT PREDICT FUTURE CROHN'S DISEASE DEVELOPMENT ARE ASSOCIATED WITH GUT BARRIER FUNCTION, SUBCLINICAL GUT INFLAMMATION AND IMMUNE RESPONSE TO BACTERIAL ANTIGENS (2022) (0)
- Establishing Normal Parameters of the Small and Large Bowel With Transabominal Ultrasound: A Retrospective Study Comparing Patients With and Without Inflammatory Bowel Disease (2011) (0)
- Su575 DIETARY PREDICTORS OF BIOLOGICAL ACTIVITY IN CROHN'S DISEASE: A RETROSPECTIVE COHORT STUDY (0)
- S760 Persistence of Tofacitinib Treatment in Patients With Ulcerative Colitis Who Entered the Open-Label, Long-Term Extension Study, OCTAVE OPEN in Remission or With a Clinical Response (2021) (0)
- S799 Health-Related Quality of Life with Guselkumab Induction and Maintenance Therapy as Measured by PROMIS-29: Results Through Week 48 of Phase 2 GALAXI 1 Study (2022) (0)
- Subject Index Vol. 30, Suppl. 3, 2012 (2013) (0)
- Sa1745 - Biological Interventions for Induction and Maintenance of Mucosal Healing in Crohn's Disease: A Cochrane Systematic Review (2018) (0)
- Sa1753 - Tofacitinib Achieves Symptomatic Improvement within 3 Days in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior Tumour Necrosis Factor Inhibitor Treatment Status: Results from Octave Induction 1 & 2 (2018) (0)
- A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES (2022) (0)
- Tu1470: RISANKIZUMAB MAINTENANCE THERAPY RESULTS IN SUSTAINED IMPROVEMENTS IN ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: POST-HOC ANALYSIS FROM THE PHASE 3 STUDY FORTIFY (2022) (0)
- S826 Baseline and Early Predictors of Response to Risankizumab Induction and Maintenance Treatment in Patients With Moderate to Severe Crohn's Disease (2022) (0)
- 842 Impact of Response and Inflammatory Burden at Start of Maintenance Therapy on Clinical Efficacy of Ustekinumab Dosing Regimen in UC: Week 44 Results From UNIFI (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Remo Panaccione?
Remo Panaccione is affiliated with the following schools:
